<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id><journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id><journal-id journal-id-type="publisher-id">ijms</journal-id><journal-title-group><journal-title>International Journal of Molecular Sciences</journal-title></journal-title-group><issn pub-type="epub">1422-0067</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27049383</article-id><article-id pub-id-type="pmc">4848953</article-id><article-id pub-id-type="doi">10.3390/ijms17040497</article-id><article-id pub-id-type="publisher-id">ijms-17-00497</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Aneurysmal Subarachnoid Hemorrhage and Neuroinflammation: A Comprehensive Review</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lucke-Wold</surname><given-names>Brandon P.</given-names></name><xref ref-type="aff" rid="af1-ijms-17-00497">1</xref><xref ref-type="author-notes" rid="fn1-ijms-17-00497">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Logsdon</surname><given-names>Aric F.</given-names></name><xref ref-type="aff" rid="af2-ijms-17-00497">2</xref><xref ref-type="author-notes" rid="fn1-ijms-17-00497">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Manoranjan</surname><given-names>Branavan</given-names></name><xref ref-type="aff" rid="af3-ijms-17-00497">3</xref></contrib><contrib contrib-type="author"><name><surname>Turner</surname><given-names>Ryan C.</given-names></name><xref ref-type="aff" rid="af1-ijms-17-00497">1</xref></contrib><contrib contrib-type="author"><name><surname>McConnell</surname><given-names>Evan</given-names></name><xref ref-type="aff" rid="af4-ijms-17-00497">4</xref></contrib><contrib contrib-type="author"><name><surname>Vates</surname><given-names>George Edward</given-names></name><xref ref-type="aff" rid="af4-ijms-17-00497">4</xref></contrib><contrib contrib-type="author"><name><surname>Huber</surname><given-names>Jason D.</given-names></name><xref ref-type="aff" rid="af2-ijms-17-00497">2</xref></contrib><contrib contrib-type="author"><name><surname>Rosen</surname><given-names>Charles L.</given-names></name><xref ref-type="aff" rid="af1-ijms-17-00497">1</xref></contrib><contrib contrib-type="author"><name><surname>Simard</surname><given-names>J. Marc</given-names></name><xref ref-type="aff" rid="af5-ijms-17-00497">5</xref><xref rid="c1-ijms-17-00497" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Prokai-Tatrai</surname><given-names>Katalin</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-ijms-17-00497"><label>1</label>Department of Neurosurgery, West Virginia University School of Medicine, Morgantown, WV 26505, USA; <email>Bwold@mix.wvu.edu</email> (B.P.L.-W.); <email>rcturner@hsc.wvu.edu</email> (R.C.T.); <email>crosen@hsc.wvu.edu</email> (C.L.R.)</aff><aff id="af2-ijms-17-00497"><label>2</label>Department of Basic Pharmaceutical Sciences, West Virginia University School of Pharmacy, Morgantown, WV 26505, USA; <email>logsdoa@gmail.com</email> (A.F.L.); <email>jdhuber@hsc.wvu.edu</email> (J.D.H.)</aff><aff id="af3-ijms-17-00497"><label>3</label>McMaster Stem Cell and Cancer Research Institute, Michael G. DeGroote School of Medicine, Hamilton, ON L8S 4K1, Canada; <email>branavan.manoranjan@medportal.ca</email></aff><aff id="af4-ijms-17-00497"><label>4</label>Department of Neurobiology and Anatomy, University of Rochester Medical Center, Rochester, NY 14642, USA; <email>evan_mcconnell@urmc.rochester.edu</email> (E.M.); <email>edward_vates@urmc.rochester.edu</email> (G.E.V.)</aff><aff id="af5-ijms-17-00497"><label>5</label>Departments of Neurosurgery, Pathology, and Physiology, University of Maryland School of Medicine, Baltimore, MD 21201, USA</aff><author-notes><corresp id="c1-ijms-17-00497"><label>*</label>Correspondence: <email>msimard@smail.umaryland.edu</email>; Tel.: +1-410-328-0850; Fax: +1-410-328-0756</corresp><fn id="fn1-ijms-17-00497"><label>&#x02020;</label><p>Denotes Equal Contribution for First Author.</p></fn></author-notes><pub-date pub-type="epub"><day>02</day><month>4</month><year>2016</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2016</year></pub-date><volume>17</volume><issue>4</issue><elocation-id>497</elocation-id><history><date date-type="received"><day>18</day><month>1</month><year>2016</year></date><date date-type="accepted"><day>28</day><month>3</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; 2016 by the authors; licensee MDPI, Basel, Switzerland.</copyright-statement><copyright-year>2016</copyright-year><license><license-p><!--CREATIVE COMMONS-->This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Aneurysmal subarachnoid hemorrhage (SAH) can lead to devastating outcomes including vasospasm, cognitive decline, and even death. Currently, treatment options are limited for this potentially life threatening injury. Recent evidence suggests that neuroinflammation plays a critical role in injury expansion and brain damage. Red blood cell breakdown products can lead to the release of inflammatory cytokines that trigger vasospasm and tissue injury. Preclinical models have been used successfully to improve understanding about neuroinflammation following aneurysmal rupture. The focus of this review is to provide an overview of how neuroinflammation relates to secondary outcomes such as vasospasm after aneurysmal rupture and to critically discuss pharmaceutical agents that warrant further investigation for the treatment of subarachnoid hemorrhage. We provide a concise overview of the neuroinflammatory pathways that are upregulated following aneurysmal rupture and how these pathways correlate to long-term outcomes. Treatment of aneurysm rupture is limited and few pharmaceutical drugs are available. Through improved understanding of biochemical mechanisms of injury, novel treatment solutions are being developed that target neuroinflammation. In the final sections of this review, we highlight a few of these novel treatment approaches and emphasize why targeting neuroinflammation following aneurysmal subarachnoid hemorrhage may improve patient care. We encourage ongoing research into the pathophysiology of aneurysmal subarachnoid hemorrhage, especially in regards to neuroinflammatory cascades and the translation to randomized clinical trials.</p></abstract><kwd-group><kwd>aneurysmal subarachnoid hemorrhage</kwd><kwd>cerebral vasospasm</kwd><kwd>neuroinflammation</kwd><kwd>novel treatments</kwd></kwd-group></article-meta></front><body><sec id="sec1-ijms-17-00497"><title>1. Introduction</title><p>Aneurysmal subarachnoid hemorrhage (SAH) can lead to devastating outcomes for patients, including cognitive decline, cerebral vasospasm (CV), and delayed cerebral ischemia [<xref rid="B1-ijms-17-00497" ref-type="bibr">1</xref>,<xref rid="B2-ijms-17-00497" ref-type="bibr">2</xref>]. The underlying mechanisms contributing to injury expansion following aneurysmal SAH are poorly understood, therefore limiting the number of effective pharmaceutical treatment options. Recent evidence implicates neuroinflammation as a key mediator of injury expansion and behavioral deficits [<xref rid="B3-ijms-17-00497" ref-type="bibr">3</xref>,<xref rid="B4-ijms-17-00497" ref-type="bibr">4</xref>]. Peripheral immune cells are both recruited and activated in damaged tissue [<xref rid="B5-ijms-17-00497" ref-type="bibr">5</xref>]. These cells can enter the brain parenchyma and release inflammatory cytokines [<xref rid="B6-ijms-17-00497" ref-type="bibr">6</xref>]. Additionally, intrinsic toll-like receptors are upregulated after infarction leading to widespread neuroinflammation [<xref rid="B7-ijms-17-00497" ref-type="bibr">7</xref>]. Furthermore, neuroinflammation has been linked to adverse secondary outcomes that occur after SAH. Vessels undergoing CV have increased leukocyte adhesion capacity contributing to delayed neurologic deterioration [<xref rid="B8-ijms-17-00497" ref-type="bibr">8</xref>,<xref rid="B9-ijms-17-00497" ref-type="bibr">9</xref>]. In this review, we highlight what is known about neuroinflammation following aneurysmal SAH. We discuss how neuroinflammation contributes to CV and delayed cerebral ischemia, how neuroinflammation susceptibility is affected by comorbidities and genetics, and the potential benefit for targeting inflammatory pathways following aneurysmal SAH. Finally, we highlight potential avenues for future study including novel treatment approaches. Articles selected for this review were based on impact factor of journal, number of overall citations, and the general impact of the article for advancing understanding of SAH mechanisms.</p></sec><sec id="sec2-ijms-17-00497"><title>2. Neuroinflammation</title><sec id="sec2dot1-ijms-17-00497"><title>2.1. The Role of Inflammation</title><p>Emerging evidence points to inflammation playing a major role in acute and chronic phases of neural injury associated with aneurysmal SAH [<xref rid="B10-ijms-17-00497" ref-type="bibr">10</xref>,<xref rid="B11-ijms-17-00497" ref-type="bibr">11</xref>]. In the following sections, we review and explore some of the pathophysiology associated with aneursymal SAH, particularly in relation to the neuroinflammatory response. We conclude the section by highlighting new avenues and suggest further studies to address lingering questions within the field of aneurysmal SAH.</p></sec><sec id="sec2dot2-ijms-17-00497"><title>2.2. SAH Pathophysiology: Acute Events</title><p>The initial aneurysmal rupture deposits blood within the subarachnoid space. Red blood cell breakdown and degradation over time leads to the deposition of hemoglobin. Methemoglobin, heme, and hemin resulting from red blood cell breakdown can lead to activation of TLR4, which signals inflammatory cascades that damage neurons and white matter [<xref rid="B12-ijms-17-00497" ref-type="bibr">12</xref>,<xref rid="B13-ijms-17-00497" ref-type="bibr">13</xref>]. Hemin has been linked with the release of redox-active iron, altering the balance of oxidants and anti-oxidants. The redox-active iron depletes anti-oxidant stores such as nicotinamide adenine dinucleotide phosphate (NADPH) and glutathione while producing superoxide and hydroxyl radicals as well as lipid peroxidation [<xref rid="B14-ijms-17-00497" ref-type="bibr">14</xref>,<xref rid="B15-ijms-17-00497" ref-type="bibr">15</xref>].</p><p>As blood leaves the confines of the vasculature following aneurysmal rupture, immunomodulatory cells within the CNS, such as microglia, are activated. These cells trigger the upregulation of numerous cell adhesion molecules within endothelial cells, which subsequently allows a multitude of inflammatory cells to bind and enter the subarachnoid space [<xref rid="B16-ijms-17-00497" ref-type="bibr">16</xref>,<xref rid="B17-ijms-17-00497" ref-type="bibr">17</xref>]. Once in the subarachnoid space, these inflammatory cells, macrophages and neutrophils, phagocytize the extravasated, degrading red blood cells [<xref rid="B12-ijms-17-00497" ref-type="bibr">12</xref>]. This process occurs in an effort to clear free hemoglobin, and promote neurostability and recovery. Hemoglobin clearance is facilitated by the binding of hemoglobin to haptoglobin for rapid engulfment by immune cells [<xref rid="B13-ijms-17-00497" ref-type="bibr">13</xref>].</p></sec><sec id="sec2dot3-ijms-17-00497"><title>2.3. SAH Pathophysiology: Subacute-Chronic Events</title><p>As described above, pre-clinical data suggest that aneurysmal SAH is associated with the attraction and subsequent deposition of neutrophils and macrophages in response to free hemoglobin and hemin. A key area requiring further investigation is how these neutrophils and macrophages are recruited and whether they pass through an intact or disrupted blood brain barrier. While these peripheral immune cells are essential for clearing hemoglobin, the cells can become trapped in the subarachnoid space due to alterations in cerebral spinal fluid (CSF) flow and the restoration of the endothelial tight junction barrier. Once trapped within the subarachnoid space, the macrophages and neutrophils undergo degranulation, which releases a multitude of inflammatory factors. A few of these include endothelins and oxidative radicals. These factors can cause inflammation-induced vasoconstriction, arterial narrowing, meningitis, and cerebritis [<xref rid="B18-ijms-17-00497" ref-type="bibr">18</xref>]. Importantly, the inflammatory response is generalized, causing the release of inflammatory cytokines, endothelial adhesion molecules, and activated complement throughout the brain [<xref rid="B19-ijms-17-00497" ref-type="bibr">19</xref>,<xref rid="B20-ijms-17-00497" ref-type="bibr">20</xref>].</p></sec><sec id="sec2dot4-ijms-17-00497"><title>2.4. Inflammatory Mediators in SAH: A Focus on Cytokines and Cell Lines</title><p>Inflammation following aneursymal SAH has been investigated in order to characterize the timing, magnitude, and site of cytokine release [<xref rid="B21-ijms-17-00497" ref-type="bibr">21</xref>,<xref rid="B22-ijms-17-00497" ref-type="bibr">22</xref>]. For example, IL-1&#x003b2;, IL-6, and TNF&#x003b1; are released into both the serum and cerebrospinal fluid following SAH [<xref rid="B23-ijms-17-00497" ref-type="bibr">23</xref>,<xref rid="B24-ijms-17-00497" ref-type="bibr">24</xref>]. Similarly, these same cytokines have been shown in animal models of SAH to be increased in the cerebral arterial wall [<xref rid="B25-ijms-17-00497" ref-type="bibr">25</xref>]. While the role that these cytokines play in SAH warrants further investigation, prevailing clinical signs such as neutrophilia, pyrexia, and general cerebral edema are likely associated with the cytokine storm [<xref rid="B26-ijms-17-00497" ref-type="bibr">26</xref>]. The current lack of clarity with regards to the beneficial or detrimental role inflammation plays following aneurysmal SAH is perhaps best exemplified by the mixed results of preclinical and clinical studies. Some clinical studies have found that modulating inflammation following SAH is beneficial while other studies have shown no beneficial effect at all [<xref rid="B27-ijms-17-00497" ref-type="bibr">27</xref>]. It is likely that activation of inflammation at different time points post rupture is associated with different protective or detrimental responses depending on the surrounding milieu and type of cells recruited to the site.</p><p>What is apparent is the prominent role inflammation plays in causing cerebral vasospasm (CV). Injection of pro-inflammatory materials/compounds intracisternally induces CV, even in the absence of blood breakdown products [<xref rid="B1-ijms-17-00497" ref-type="bibr">1</xref>]. Clinically, the inflammatory response appears in close temporal relationship with the spasm and in direct proportion to the magnitude of the inflammatory response [<xref rid="B28-ijms-17-00497" ref-type="bibr">28</xref>]. These findings have been supported by evidence suggesting that accumulation of inflammatory cells closely parallels neuronal cell death. Cell death near the vasculature has been substantially reduced by depletion of inflammatory cells in preclinical studies [<xref rid="B29-ijms-17-00497" ref-type="bibr">29</xref>].</p><p>A substantial knowledge gap persists in understanding the adaptive immune response in SAH. Emerging evidence from preclinical studies has implicated B and T lymphocyte infiltration into the vessel wall of aneurysms, which may potentially promote aneurysmal rupture and SAH [<xref rid="B30-ijms-17-00497" ref-type="bibr">30</xref>,<xref rid="B31-ijms-17-00497" ref-type="bibr">31</xref>]. Preliminary data from clinical studies indicate a diffuse presence of not only innate immune cells but also adaptive immune cell populations in the CSF and serum following SAH [<xref rid="B5-ijms-17-00497" ref-type="bibr">5</xref>]. While it is difficult to draw conclusions based upon this preliminary study, it is promising in that a new therapeutic target and avenue may be available in the future [<xref rid="B32-ijms-17-00497" ref-type="bibr">32</xref>,<xref rid="B33-ijms-17-00497" ref-type="bibr">33</xref>]. CSF biomarkers may be used to guide physicians on the appropriate selection of pharmaceutical agents.</p></sec><sec id="sec2dot5-ijms-17-00497"><title>2.5. Inflammatory Mediators in SAH: A Focus on Proteases</title><p>Additional inflammation-specific SAH studies have focused on matrix metalloproteinases (MMPs), a family of proteases consisting of multiple subtypes. The most widely investigated of these being MMP-9 [<xref rid="B34-ijms-17-00497" ref-type="bibr">34</xref>,<xref rid="B35-ijms-17-00497" ref-type="bibr">35</xref>]. MMP-9 has been shown to be responsible for the degradation of tight junction proteins, which are critical in the maintenance of blood-brain barrier (BBB) integrity. Notably, clinical studies of SAH have reported an elevation of MMP-9 in brain tissue, serum, and cerebrospinal fluid [<xref rid="B36-ijms-17-00497" ref-type="bibr">36</xref>,<xref rid="B37-ijms-17-00497" ref-type="bibr">37</xref>]. Consistent with cytokine studies, MMP-9 is elevated not only in serum and CSF but also in the vessel wall [<xref rid="B25-ijms-17-00497" ref-type="bibr">25</xref>]. These studies document a potential novel approach for treatment of SAH. By targeting MMP-9 in the vessel wall, it could be possible to restore BBB integrity or prevent BBB disruption from occurring in the first place. Preventing basement membrane degradation could facilitate enhanced reconstitution of tight junction protein binding.</p></sec><sec id="sec2dot6-ijms-17-00497"><title>2.6. SAH-Associated Inflammation: An Inflow or an Outflow Problem?</title><p>CSF flow disruption is associated with inflammation following SAH [<xref rid="B38-ijms-17-00497" ref-type="bibr">38</xref>]. This is consistent with clinical symptoms where obstructive hydrocephalus is commonly reported due to the presumed breakdown of blood products in the subarachnoid space and subsequent obstruction of CSF drainage pathways. The etiology of this condition is actually poorly understood and may in fact be due to obstruction of the glymphatic system described by Nedergaard and colleagues [<xref rid="B39-ijms-17-00497" ref-type="bibr">39</xref>]. The system is critical for CSF circulation and consists of multiple channels around the vasculature. While the glymphatic system remains under investigation in several neurological injury models such as traumatic brain injury, what has already been elucidated is that the system plays a critical role in elimination of metabolic waste products both during normal homeostasis and after injury. The glymphatic system functionality can be altered in the context of neural injury, such as traumatic brain injury, as well as in sleep deprivation [<xref rid="B40-ijms-17-00497" ref-type="bibr">40</xref>]. Ongoing preclinical studies are being conducted to determine if the glymphatic system is disrupted following aneurysmal SAH. We expect SAH to cause a significant disruption in glymphatic flow. How this knowledge can be utilized for enhancing treatment after SAH is unclear but will likely be of value clinically and therapeutically. Agents that can restore glymphatic flow will be of value clinically.</p><p>Another challenge with regards to modulating inflammation is the fact that inflammation is often observed to be biphasic in nature, with elements that are both protective as well as deleterious. Identifying this temporal relationship and when to target involved pathways for therapeutic benefit remains a substantial challenge. The magnitude of the inflammatory response may dictate outcome, and warrants further investigation with preclinical models. Advanced neuroimaging may offer a viable option to detect biphasic peaks in the neuroinflammatory cascade. Finally, utilizing current knowledge regarding SAH pathophysiology offers clear advantages therapeutically. For example, patients with the haptoglobin &#x003b1;1&#x02013;&#x003b1;1 subunit compared to the haptoglobin &#x003b1;2&#x02013;&#x003b1;2 subunit have decreased risk of CV following aneurysmal SAH, indicating a potential therapeutic target [<xref rid="B41-ijms-17-00497" ref-type="bibr">41</xref>].</p></sec></sec><sec id="sec3-ijms-17-00497"><title>3. Secondary Outcomes</title><sec id="sec3dot1-ijms-17-00497"><title>3.1. Cerebral Vasospasm</title><p>Aneurysmal SAH can lead to CV, which is the narrowing of blood vessels within the subarachnoid space of the brain [<xref rid="B42-ijms-17-00497" ref-type="bibr">42</xref>]. It is a serious complication often experienced by aneurysmal SAH survivors [<xref rid="B43-ijms-17-00497" ref-type="bibr">43</xref>,<xref rid="B44-ijms-17-00497" ref-type="bibr">44</xref>]. If CV persists, insufficient blood flow reaches affected regions of the brain, causing delayed cerebral ischemia [<xref rid="B45-ijms-17-00497" ref-type="bibr">45</xref>]. CV is characterized by progressive narrowing of cerebral arteries beginning no earlier than day three following hemorrhage and peaking at one week [<xref rid="B46-ijms-17-00497" ref-type="bibr">46</xref>]. Clinically, CV leads to delayed cerebral ischemia and infarction in 20%&#x02013;30% of patients [<xref rid="B47-ijms-17-00497" ref-type="bibr">47</xref>]. While the etiology of CV remains unknown, spasmogenic and neuroinflammatory substances generated from the lysis of subarachnoid blood are thought to drive the process [<xref rid="B48-ijms-17-00497" ref-type="bibr">48</xref>]. Given that few treatments effectively target CV, novel murine models have been developed to further elucidate the mechanisms that regulate CV. Specifically, models have been designed to simulate vasodilatory mechanisms of the cerebral vasculature [<xref rid="B49-ijms-17-00497" ref-type="bibr">49</xref>,<xref rid="B50-ijms-17-00497" ref-type="bibr">50</xref>,<xref rid="B51-ijms-17-00497" ref-type="bibr">51</xref>,<xref rid="B52-ijms-17-00497" ref-type="bibr">52</xref>]. One mouse model involves endovascular perforation of the middle cerebral artery to produce the hemorrhage [<xref rid="B51-ijms-17-00497" ref-type="bibr">51</xref>,<xref rid="B52-ijms-17-00497" ref-type="bibr">52</xref>]. Another CV model consists of injecting femoral arterial blood intradurally through the atlanto-occipital membrane [<xref rid="B50-ijms-17-00497" ref-type="bibr">50</xref>]. A canine model has been established with double hemorrhage that reliably produces CV [<xref rid="B53-ijms-17-00497" ref-type="bibr">53</xref>]. Although all the models generate vascular changes consistent with CV, the endovascular perforation model is much more lethal, with a mortality of 29% [<xref rid="B51-ijms-17-00497" ref-type="bibr">51</xref>,<xref rid="B52-ijms-17-00497" ref-type="bibr">52</xref>], compared to the 3% in the intradural injection model [<xref rid="B50-ijms-17-00497" ref-type="bibr">50</xref>].</p></sec><sec id="sec3dot2-ijms-17-00497"><title>3.2. CV and Inflammation</title><p>Growing evidence supports a role for neuroinflammation in the pathogenesis of CV [<xref rid="B48-ijms-17-00497" ref-type="bibr">48</xref>,<xref rid="B54-ijms-17-00497" ref-type="bibr">54</xref>]. Preclinical models of CV have repeatedly demonstrated the presence of cytokine upregulation and neutrophil activation. Active neutrophils can promote reactive oxygen species formation, which has been implicated in vascular pathology [<xref rid="B55-ijms-17-00497" ref-type="bibr">55</xref>]. Further work needs to be done in order to elucidate the mechanisms by which these neutrophils are recruited to the site of rupture. In human clinical studies, the cerebrospinal fluid (CSF) neutrophil percentage is an independent predictor of CV in SAH patients [<xref rid="B55-ijms-17-00497" ref-type="bibr">55</xref>]. Specifically, a CSF neutrophil content of &#x0003e;62% on day three following a SAH serves as an independent predictor for developing CV [<xref rid="B55-ijms-17-00497" ref-type="bibr">55</xref>]. Therefore, the resulting neutrophil-mediated inflammatory process offers a potential therapeutic window for the treatment and prevention of CV.</p><p>While specific cell types may have unique roles in initiating CV, shared signaling pathways within these distinct populations may converge on common downstream effectors to drive CV. Heme released from hemoglobin has been shown in a preclinical model to promote a significant neuroinflammatory response, in part through signaling via toll-like receptor 4 (TLR4) [<xref rid="B56-ijms-17-00497" ref-type="bibr">56</xref>,<xref rid="B57-ijms-17-00497" ref-type="bibr">57</xref>]. TLR4 subsequently interacts with downstream effectors to generate a bimodal nuclear factor kappa beta (NF&#x003ba;B)-dependent inflammatory response (<xref ref-type="fig" rid="ijms-17-00497-f001">Figure 1</xref>) [<xref rid="B58-ijms-17-00497" ref-type="bibr">58</xref>,<xref rid="B59-ijms-17-00497" ref-type="bibr">59</xref>,<xref rid="B60-ijms-17-00497" ref-type="bibr">60</xref>]. TLR4<sup>&#x02212;/&#x02212;</sup> mice demonstrate a significant reduction in CV following SAH when compared to wild-type mice. Interestingly, TLR4 agonists alter the degree of CV in TLR4<sup>&#x02212;/&#x02212;</sup> mice such that it mimics wild-type mice [<xref rid="B58-ijms-17-00497" ref-type="bibr">58</xref>]. Furthermore, attenuation of the TLR4 and NF&#x003ba;B-dependent inflammatory response reduced the expression of downstream pro-inflammatory factors and provided a neuroprotective role in an aneurysmal SAH model [<xref rid="B61-ijms-17-00497" ref-type="bibr">61</xref>]. These studies further establish TLR4 as a critical component in the CV cascade. Although TLR4 is expressed across many cell types, it is mostly expressed in microglia during the bimodal phases of CV [<xref rid="B58-ijms-17-00497" ref-type="bibr">58</xref>]. Depletion of microglia <italic>in vivo</italic> following SAH is able to significantly reduce the extent of CV during both phases of the cascade [<xref rid="B58-ijms-17-00497" ref-type="bibr">58</xref>]. However, the limited clinical utility in depleting microglia is apparent. Therapeutics that can dampen the microglia response may be beneficial however in reducing this inflammatory cascade.</p></sec><sec id="sec3dot3-ijms-17-00497"><title>3.3. CV and Long-Term Deficits</title><p>Whereas CV represents an acute concern in SAH patients, lasting cognitive deficits are a common long-term complication observed in aneurysmal SAH survivors [<xref rid="B62-ijms-17-00497" ref-type="bibr">62</xref>]. SAH survivors also experience functional impairments in their ability to perform daily activities [<xref rid="B62-ijms-17-00497" ref-type="bibr">62</xref>]. An assessment of grey- and white-matter damage following aneurysmal SAH in rats demonstrated a significant decrease in the neuronal marker microtubule-associated protein 2 and myelin basic protein, respectively [<xref rid="B63-ijms-17-00497" ref-type="bibr">63</xref>]. Glial fibrillary acidic protein (GFAP), a marker of astrocytes, was increased in rat brains following SAH suggesting the presence of reactive gliosis [<xref rid="B63-ijms-17-00497" ref-type="bibr">63</xref>]. Activated astrocytes can form glial scars, which are protective in the acute phase of brain injury by establishing a clear boundary between damaged and healthy tissue and thereby preventing the spread of pro-inflammatory signals throughout the brain [<xref rid="B64-ijms-17-00497" ref-type="bibr">64</xref>,<xref rid="B65-ijms-17-00497" ref-type="bibr">65</xref>]. However, ongoing reactive gliosis and scar formation may inhibit axonal regrowth and remyelination, further promoting grey- and white-matter damage in response to a persistent inflammatory response [<xref rid="B66-ijms-17-00497" ref-type="bibr">66</xref>]. Targeting the chronic but not acute gliosis may be a viable treatment option worth further study.</p><p>The effects of aneursymal SAH can also result in acute and long-term functional deficits in sensorimotor behavior [<xref rid="B63-ijms-17-00497" ref-type="bibr">63</xref>]. Both mechanical sensitivity to innocuous stimuli and fine sensorimotor function were significantly impaired in SAH-induced rats when compared to sham-operated controls [<xref rid="B63-ijms-17-00497" ref-type="bibr">63</xref>]. Therefore, it appears that the cognitive and functional deficits observed in SAH preclinical models and patients are primarily a consequence of the persistent neuroinflammatory process observed in these patients during the acute and later stages of recovery.</p></sec></sec><sec id="sec4-ijms-17-00497"><title>4. Etiology and Comorbidities</title><sec id="sec4dot1-ijms-17-00497"><title>4.1. Genetic Factors</title><p>Age is a determining factor of outcome following aneurysmal SAH [<xref rid="B67-ijms-17-00497" ref-type="bibr">67</xref>]. Aged vessels are less compliant and have weak muscular walls. Premature vascular aging contributes to an increased risk of aneurysmal rupture and subsequent hemorrhage. Patients pre-disposed to epoxyeicosatrienoic acid upregulation are more at risk for vascular dysfunction and aneurysmal rupture [<xref rid="B68-ijms-17-00497" ref-type="bibr">68</xref>,<xref rid="B69-ijms-17-00497" ref-type="bibr">69</xref>]. Mutations in <italic>VCAN</italic> gene have also been linked to SAH [<xref rid="B70-ijms-17-00497" ref-type="bibr">70</xref>]. Neuroinflammation severely damages already dysfunctional vessels. After rupture has occurred, mutations in the 9p21 locus on gene <italic>CDKN2A</italic> increases neuroinflammation [<xref rid="B71-ijms-17-00497" ref-type="bibr">71</xref>]. Interleukin 6 polymorphisms can also augment neuroinflammation and can worsen SAH outcomes [<xref rid="B72-ijms-17-00497" ref-type="bibr">72</xref>]. Interestingly, patients with the haptoglobin phenotype Hp2-2 have increased susceptibility for CV post-rupture [<xref rid="B73-ijms-17-00497" ref-type="bibr">73</xref>], which, as discussed above, may be mediated by neuroinflammation.</p><p>The apolipoprotein-&#x003b5;4 allele has been associated with poor cognitive performance several years following aneursymal SAH in patients [<xref rid="B74-ijms-17-00497" ref-type="bibr">74</xref>]. Certain polymorphisms of the <italic>A1166C</italic> gene, which regulates angiotensin II type 1 receptors, have also been correlated to worsened outcome after aneurysmal SAH [<xref rid="B75-ijms-17-00497" ref-type="bibr">75</xref>]. These genetic associations are poorly understood in the clinical population. Pre-clinical genetic studies however have shed light on the role that neuroinflammation plays in injury progression.</p><p>In a rat SAH model, high-mobility group box 1 triggers NF&#x003ba;B translocation thereby promoting neuroinflammation (<xref ref-type="fig" rid="ijms-17-00497-f001">Figure 1</xref>) [<xref rid="B76-ijms-17-00497" ref-type="bibr">76</xref>]. The subsequent release of TNF&#x003b1; severely compromises vascular integrity around the site of SAH [<xref rid="B77-ijms-17-00497" ref-type="bibr">77</xref>]. Recently, Chen and colleagues discovered that the P2X7R/cryopyrosin inflammasome axis is genetically primed in certain rodent strains, which contributes to a surge in interleukin 1&#x003b2; (IL-1&#x003b2;) following aneurysmal SAH [<xref rid="B78-ijms-17-00497" ref-type="bibr">78</xref>]. Future clinical studies are needed to verify how these pathways are altered in patients with SAH. The sulfonylurea receptor 1-transient receptor potential melastatin 4 (Sur1-TRPM4) channel was found to be transcriptionally upregulated by <italic>Abcc8</italic> and <italic>Trpm4</italic> in rodents and humans following SAH [<xref rid="B79-ijms-17-00497" ref-type="bibr">79</xref>]. This phylogenetically conserved phenomenon makes it an ideal target for pharmacologic intervention, which we will discuss further in the concluding sections.</p></sec><sec id="sec4dot2-ijms-17-00497"><title>4.2. Comorbidities and Physical Correlates</title><p>Patients with underlying comorbidities often fare worse following aneursymal SAH. Patients with migraine headaches are at increased risk for SAH [<xref rid="B80-ijms-17-00497" ref-type="bibr">80</xref>]. Diabetes mellitus type II is associated with an increased risk for CV following SAH [<xref rid="B81-ijms-17-00497" ref-type="bibr">81</xref>]. Patients with hypertension have larger subdural clot volumes following SAH [<xref rid="B82-ijms-17-00497" ref-type="bibr">82</xref>]. Only recently have investigators begun to look at the mechanistic links between these comorbidities and outcome.</p><p>The heart and brain are intimately connected through the vasculature and nerves. Once the brain becomes damaged from aneurysmal SAH, parasympathetic dysfunction may contribute to cardiac arrhythmias, leading to the release of inflammatory cytokines that enter the vasculature [<xref rid="B83-ijms-17-00497" ref-type="bibr">83</xref>]. Modified vascular markers released following aneurysm rupture can interact with cytokines from damaged heart tissue and have been shown in a preclinical model to perpetuate inflammation within the brain (<xref ref-type="fig" rid="ijms-17-00497-f002">Figure 2</xref>) [<xref rid="B84-ijms-17-00497" ref-type="bibr">84</xref>]. Preclinical data have shown that activated neutrophils in the peripheral vasculature can likewise damage brain microvessels following SAH [<xref rid="B85-ijms-17-00497" ref-type="bibr">85</xref>]. Leukocyte diapedesis can occur through damaged microvessels following injury. Many peripheral immune cells migrate into the cerebral spinal fluid and the brain [<xref rid="B86-ijms-17-00497" ref-type="bibr">86</xref>].</p><p>Inflammatory factors released from the damaged heart can perpetuate inflammation in the brain by means of an inflammatory circuit [<xref rid="B83-ijms-17-00497" ref-type="bibr">83</xref>]. When comorbidities are present, this inflammatory circuit is accelerated [<xref rid="B87-ijms-17-00497" ref-type="bibr">87</xref>]. Adipokines from excess fat storage can increase neuroinflammation susceptibility after brain injury [<xref rid="B88-ijms-17-00497" ref-type="bibr">88</xref>]. Evidence suggests that atherosclerosis and diabetes can prime the immune system and exacerbate an inflammatory response during SAH [<xref rid="B89-ijms-17-00497" ref-type="bibr">89</xref>]. Further investigation with clinical studies is needed to elucidate additional factors contributing to neuroinflammation in aneursymal SAH patients with comorbidities and/or the metabolic syndrome.</p></sec></sec><sec id="sec5-ijms-17-00497"><title>5. Targeting Neuroinflammation</title><sec id="sec5dot1-ijms-17-00497"><title>5.1. Treatment</title><p>SAH can lead to devastating outcomes such as cognitive decline, CV, and delayed cerebral ischemia. The most common cause of SAH and the focus of this review is cerebral aneurysm rupture. The prevalence of cognitive decline and CV is high in surviving aneurysmal SAH patients. Patients who survive SAH surgery often display functional deficits in addition to long-term memory deficits [<xref rid="B90-ijms-17-00497" ref-type="bibr">90</xref>]. SAH symptoms have proven difficult to prevent; however, an effective treatment algorithm can improve outcome and increase quality of life for surviving SAH patients.</p><p>The initial treatment for SAH after cerebral aneurysm rupture is to regulate and control extremes of blood pressure. Captopril and losartan act on the renin-angiotensin system and have been shown to reduce hemorrhage post-rupture and regulate blood pressure [<xref rid="B91-ijms-17-00497" ref-type="bibr">91</xref>]. Nimodipine is a calcium channel blocker that has been shown to reduce poor outcome post-rupture [<xref rid="B92-ijms-17-00497" ref-type="bibr">92</xref>]. Another drug that has been employed clinically to target neuroinflammation is an IL-1 receptor antagonist, which has been shown to reduce inflammatory cytokine levels within the CSF of patients with aneurysmal SAH [<xref rid="B93-ijms-17-00497" ref-type="bibr">93</xref>]. TNF&#x003b1; inhibitors are also currently under investigation and warrant further consideration [<xref rid="B4-ijms-17-00497" ref-type="bibr">4</xref>]. In order to improve available treatments, it is imperative that investigative work continues in pre-clinical models and that novel approaches for reducing neuroinflammation be developed.</p></sec><sec id="sec5dot2-ijms-17-00497"><title>5.2. Lessons from Animal Models</title><p>SAH models have produced similar deficits to those seen in patients following aneurysm rupture [<xref rid="B61-ijms-17-00497" ref-type="bibr">61</xref>,<xref rid="B63-ijms-17-00497" ref-type="bibr">63</xref>,<xref rid="B94-ijms-17-00497" ref-type="bibr">94</xref>,<xref rid="B95-ijms-17-00497" ref-type="bibr">95</xref>]. CV followed by delayed cerebral ischemia is a detrimental physiological outcome seen in patients with SAH. In a rodent model of SAH, vasoconstrictive receptor upregulation provided evidence of CV followed by delayed cerebral ischemia [<xref rid="B96-ijms-17-00497" ref-type="bibr">96</xref>]. A recent study proposed that the MEK1/2 pathway regulates multiple contractile receptors and may be a viable target for reducing delayed ischemia after aneurysmal SAH [<xref rid="B97-ijms-17-00497" ref-type="bibr">97</xref>].</p><p>Inflammation following delayed cerebral ischemia has been linked clinically to memory and functional deficits in SAH patients as discussed above. In light of this, many studies have focused on understanding inflammatory cascade activation in preclinical models of SAH (<xref ref-type="table" rid="ijms-17-00497-t001">Table 1</xref>). Recently, groups have begun to investigate neuroprotective agents that may mitigate these inflammatory cascades. Maddahi and colleagues showed that mitogen activated protein kinase (MAPK) pathway inhibition reduced inflammation in a rodent model of SAH [<xref rid="B98-ijms-17-00497" ref-type="bibr">98</xref>]. Previous work in spinal cord injury [<xref rid="B99-ijms-17-00497" ref-type="bibr">99</xref>], intracerebral hemorrhage [<xref rid="B100-ijms-17-00497" ref-type="bibr">100</xref>], brain ischemia [<xref rid="B101-ijms-17-00497" ref-type="bibr">101</xref>], and hypoxic-ischemic brain injury [<xref rid="B102-ijms-17-00497" ref-type="bibr">102</xref>] have implicated a neuroprotective role for the breast cancer chemotherapeutic agent, tamoxifen. Tamoxifen administration in a rat SAH model decreased inflammation, and the rats demonstrated no evidence of early brain damage such as cortical edema and BBB disruption [<xref rid="B61-ijms-17-00497" ref-type="bibr">61</xref>]. Most strikingly, tamoxifen-treated rats had complete reversal of their SAH-induced spatial working memory dysfunction compared to vehicle-treated controls [<xref rid="B61-ijms-17-00497" ref-type="bibr">61</xref>].</p><p>Peripheral immune cell adhesion and infiltration is yet another common secondary effect following SAH. This finding was elucidated first in rodent SAH models. The drug, LJP-1586, was shown to block vascular adhesion protein 1 and reduce leukocyte trafficking after SAH [<xref rid="B103-ijms-17-00497" ref-type="bibr">103</xref>]. LJP-1586 provided improved cognitive and functional performance after SAH. Moreover, the immunomodulator, fingolimod, reduced leukocyte adhesion and improved neurological outcome in the EP model of SAH [<xref rid="B104-ijms-17-00497" ref-type="bibr">104</xref>]. Preventing the infiltration of peripheral immune cells into the brain can reduce inflammation and improve neurological outcome following aneurysmal SAH. These early studies indicate that targeting neuroinflammation following SAH could be a viable therapeutic option for patients, and warrants further investigation in randomized clinical trials.</p><p>Treatment of CV is also the subject of ongoing studies. Potential therapeutic targets include E-selectin [<xref rid="B105-ijms-17-00497" ref-type="bibr">105</xref>], a trafficking molecule for neutrophils and other inflammatory cells across the vascular endothelium, and CD11/CD18 [<xref rid="B106-ijms-17-00497" ref-type="bibr">106</xref>], an adhesion molecule for neutrophils and macrophages. Preclinical therapeutics that block E-selectin [<xref rid="B105-ijms-17-00497" ref-type="bibr">105</xref>] or antibodies administered against CD11/CD18 [<xref rid="B106-ijms-17-00497" ref-type="bibr">106</xref>] have demonstrated a dramatic reduction in the severity of CV. These findings provide a proof-of-concept for treating CV by targeting neutrophils and preventing immune infiltration.</p><p>Additional therapies that target the myeloid lineage may elucidate a new role for these cells in the development of CV [<xref rid="B107-ijms-17-00497" ref-type="bibr">107</xref>]. Ly6G/C is a cell surface marker unique to the myeloid lineage and primarily found on neutrophils and monocytes with some expression on CD8+ T-cells [<xref rid="B108-ijms-17-00497" ref-type="bibr">108</xref>]. Myeloid cell depletion using an anti-Ly6G/C antibody prior to experimental SAH completely diminished angiographic CV as measured by middle cerebral artery diameter, and resulted in improved behavioral tests [<xref rid="B107-ijms-17-00497" ref-type="bibr">107</xref>]. However, the clinical utility of depleting myeloid cells in intensive care patients is confounded by the increased risk of infection.</p></sec><sec id="sec5dot3-ijms-17-00497"><title>5.3. Novel Discoveries</title><p>Treatment options typically used for peripheral diseases are now being investigated for reducing the secondary effects of aneurysmal SAH. The anticoagulant, heparin, reduced inflammation and apoptosis in a rat model of SAH [<xref rid="B109-ijms-17-00497" ref-type="bibr">109</xref>]. Tosun and colleagues investigated neuroinflammation and found the important involvement of Sur1-Trpm4 [<xref rid="B79-ijms-17-00497" ref-type="bibr">79</xref>]. This receptor can be selectively inhibited with glibenclamide (glyburide), which was shown to reduce inflammation and behavioral deficits in a rodent model of SAH [<xref rid="B79-ijms-17-00497" ref-type="bibr">79</xref>]. Glibenclamide is also a viable treatment option for ischemic and hemorrhagic stroke [<xref rid="B3-ijms-17-00497" ref-type="bibr">3</xref>], and is now currently in phase II clinical trials for acute CNS injury [<xref rid="B110-ijms-17-00497" ref-type="bibr">110</xref>].</p><p>To expand these findings, Dumont and colleagues proposed that CV may be mediated by inflammatory cytokines after SAH [<xref rid="B111-ijms-17-00497" ref-type="bibr">111</xref>]. This idea is supported by the detection of vascular adhesion molecules in serum and CSF of SAH patients. The vascular molecules trigger a robust release of inflammatory cytokines [<xref rid="B112-ijms-17-00497" ref-type="bibr">112</xref>]. Antioxidant therapies in rodent SAH models have shown promising results for reducing inflammation-mediated CV. The antioxidant rosiglitazone reduced CV and improved neurological outcome in both a rodent [<xref rid="B113-ijms-17-00497" ref-type="bibr">113</xref>], and a rabbit model of SAH [<xref rid="B114-ijms-17-00497" ref-type="bibr">114</xref>]. Additionally, glutamate toxicity has been shown to play an important role in the neuroinflammatory cascade and injury expansion following SAH [<xref rid="B115-ijms-17-00497" ref-type="bibr">115</xref>]. Glutamate modulation was shown to reduce signs of CV in both human endothelial cells and in a mouse model of SAH [<xref rid="B116-ijms-17-00497" ref-type="bibr">116</xref>].</p></sec></sec><sec id="sec6-ijms-17-00497"><title>6. Conclusions</title><p>Aneurysmal SAH continues to be a difficult clinical paradigm to treat with limited pharmacologic agents. New research has emerged that requires a careful re-examination of the role of neuroinflammation in CV, subsequent delayed cerebral ischemia, and overall patient outcome. Hemoglobin breaks down within the subarachnoid space and can trigger a robust inflammatory response. This response is coupled with an influx of peripheral immune cells and activation of innate immune cells within the brain. Additionally, genetic predisposition and associated comorbidities show that neuroinflammation itself might play a role in generating aneurysmal SAH. Novel treatment options targeting these neuroinflammatory cascades have proved efficacious in pre-clinical models for preventing CV, reducing delayed ischemia, and limiting long-term cognitive deficits (<xref ref-type="table" rid="ijms-17-00497-t001">Table 1</xref>). These treatments should be rigorously evaluated in randomized double-blinded clinical trials. It is imperative going forward that research regarding the pathophysiology of SAH as it relates to neuroinflammation coincides with the search for drug discovery. This double-edged sword married with the appropriate preclinical models offers the best option for ultimate clinical success. Facilitating the translation of novel drugs from pre-clinical studies to clinical trials is essential for improving treatment options for patients with SAH.</p></sec></body><back><ack><title>Acknowledgments</title><p>Brandon Lucke-Wold and Aric Logsdon received funding from an American Foundation of Pharmaceutical Education Predoctoral Grant. Brandon Lucke-Wold received funding from an American Medical Association Seed Grant, Sigma Xi Grants-in-Aid of Research grant, and a Neurosurgery Research and Education Foundation Medical Student Summer Research Fellowship.</p></ack><notes><title>Author Contributions</title><p>Brandon P. Lucke-Wold&#x02014;manuscript outline and organization, mechanisms section, formatting, and review. Aric F. Logsdon&#x02014;treatment section and figures. Branavan Manoranjan&#x02014;vasospasm section. Ryan C. Turner&#x02014;inflammation section and critical review. Evan McConnell and George Edward Vates&#x02014;guidance and writing related to preclinical models. Jason D. Huber and Charles L. Rosen&#x02014;critical review of manuscript in regards to treatment and clinical relevance. J. Marc Simard&#x02014;originated review idea, critical review, and organization.</p></notes><notes><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-ijms-17-00497"><label>1.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Miller</surname><given-names>B.A.</given-names></name><name><surname>Turan</surname><given-names>N.</given-names></name><name><surname>Chau</surname><given-names>M.</given-names></name><name><surname>Pradilla</surname><given-names>G.</given-names></name></person-group>
<article-title>Inflammation, vasospasm, and brain injury after subarachnoid hemorrhage</article-title>
<source>BioMed Res. Int.</source>
<year>2014</year>
<volume>2014</volume>
<fpage>384342</fpage>
<pub-id pub-id-type="doi">10.1155/2014/384342</pub-id>
<pub-id pub-id-type="pmid">25105123</pub-id></element-citation></ref><ref id="B2-ijms-17-00497"><label>2.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guresir</surname><given-names>E.</given-names></name><name><surname>Vasiliadis</surname><given-names>N.</given-names></name><name><surname>Konczalla</surname><given-names>J.</given-names></name><name><surname>Raab</surname><given-names>P.</given-names></name><name><surname>Hattingen</surname><given-names>E.</given-names></name><name><surname>Seifert</surname><given-names>V.</given-names></name><name><surname>Vatter</surname><given-names>H.</given-names></name></person-group>
<article-title>Erythropoietin prevents delayed hemodynamic dysfunction after subarachnoid hemorrhage in a randomized controlled experimental setting</article-title>
<source>J. Neurol. Sci.</source>
<year>2013</year>
<volume>332</volume>
<fpage>128</fpage>
<lpage>135</lpage>
<pub-id pub-id-type="doi">10.1016/j.jns.2013.07.004</pub-id>
<pub-id pub-id-type="pmid">23907045</pub-id></element-citation></ref><ref id="B3-ijms-17-00497"><label>3.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Caffes</surname><given-names>N.</given-names></name><name><surname>Kurland</surname><given-names>D.B.</given-names></name><name><surname>Gerzanich</surname><given-names>V.</given-names></name><name><surname>Simard</surname><given-names>J.M.</given-names></name></person-group>
<article-title>Glibenclamide for the treatment of ischemic and hemorrhagic stroke</article-title>
<source>Int. J. Mol. Sci.</source>
<year>2015</year>
<volume>16</volume>
<fpage>4973</fpage>
<lpage>4984</lpage>
<pub-id pub-id-type="doi">10.3390/ijms16034973</pub-id>
<pub-id pub-id-type="pmid">25749474</pub-id></element-citation></ref><ref id="B4-ijms-17-00497"><label>4.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Makino</surname><given-names>H.</given-names></name><name><surname>Tada</surname><given-names>Y.</given-names></name><name><surname>Wada</surname><given-names>K.</given-names></name><name><surname>Liang</surname><given-names>E.I.</given-names></name><name><surname>Chang</surname><given-names>M.</given-names></name><name><surname>Mobashery</surname><given-names>S.</given-names></name><name><surname>Kanematsu</surname><given-names>Y.</given-names></name><name><surname>Kurihara</surname><given-names>C.</given-names></name><name><surname>Palova</surname><given-names>E.</given-names></name><name><surname>Kanematsu</surname><given-names>M.</given-names></name><etal/></person-group>
<article-title>Pharmacological stabilization of intracranial aneurysms in mice: A feasibility study</article-title>
<source>Stroke</source>
<year>2012</year>
<volume>43</volume>
<fpage>2450</fpage>
<lpage>2456</lpage>
<pub-id pub-id-type="doi">10.1161/STROKEAHA.112.659821</pub-id>
<pub-id pub-id-type="pmid">22798328</pub-id></element-citation></ref><ref id="B5-ijms-17-00497"><label>5.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Moraes</surname><given-names>L.</given-names></name><name><surname>Grille</surname><given-names>S.</given-names></name><name><surname>Morelli</surname><given-names>P.</given-names></name><name><surname>Mila</surname><given-names>R.</given-names></name><name><surname>Trias</surname><given-names>N.</given-names></name><name><surname>Brugnini</surname><given-names>A.</given-names></name><name><surname>N</surname><given-names>L.L.</given-names></name><name><surname>Biestro</surname><given-names>A.</given-names></name><name><surname>Lens</surname><given-names>D.</given-names></name></person-group>
<article-title>Immune cells subpopulations in cerebrospinal fluid and peripheral blood of patients with aneurysmal subarachnoid hemorrhage</article-title>
<source>SpringerPlus</source>
<year>2015</year>
<volume>4</volume>
<fpage>195</fpage>
<pub-id pub-id-type="doi">10.1186/s40064-015-0970-2</pub-id>
<pub-id pub-id-type="pmid">25977890</pub-id></element-citation></ref><ref id="B6-ijms-17-00497"><label>6.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kooijman</surname><given-names>E.</given-names></name><name><surname>Nijboer</surname><given-names>C.H.</given-names></name><name><surname>van Velthoven</surname><given-names>C.T.</given-names></name><name><surname>Kavelaars</surname><given-names>A.</given-names></name><name><surname>Kesecioglu</surname><given-names>J.</given-names></name><name><surname>Heijnen</surname><given-names>C.J.</given-names></name></person-group>
<article-title>The rodent endovascular puncture model of subarachnoid hemorrhage: Mechanisms of brain damage and therapeutic strategies</article-title>
<source>J. Neuroinflamm.</source>
<year>2014</year>
<volume>11</volume>
<fpage>2</fpage>
<pub-id pub-id-type="doi">10.1186/1742-2094-11-2</pub-id>
<pub-id pub-id-type="pmid">24386932</pub-id></element-citation></ref><ref id="B7-ijms-17-00497"><label>7.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kwon</surname><given-names>M.S.</given-names></name><name><surname>Woo</surname><given-names>S.K.</given-names></name><name><surname>Kurland</surname><given-names>D.B.</given-names></name><name><surname>Yoon</surname><given-names>S.H.</given-names></name><name><surname>Palmer</surname><given-names>A.F.</given-names></name><name><surname>Banerjee</surname><given-names>U.</given-names></name><name><surname>Iqbal</surname><given-names>S.</given-names></name><name><surname>Ivanova</surname><given-names>S.</given-names></name><name><surname>Gerzanich</surname><given-names>V.</given-names></name><name><surname>Simard</surname><given-names>J.M.</given-names></name></person-group>
<article-title>Methemoglobin is an endogenous toll-like receptor 4 ligand-relevance to subarachnoid hemorrhage</article-title>
<source>Int. J. Mol. Sci.</source>
<year>2015</year>
<volume>16</volume>
<fpage>5028</fpage>
<lpage>5046</lpage>
<pub-id pub-id-type="doi">10.3390/ijms16035028</pub-id>
<pub-id pub-id-type="pmid">25751721</pub-id></element-citation></ref><ref id="B8-ijms-17-00497"><label>8.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Provencio</surname><given-names>J.J.</given-names></name><name><surname>Badjatia</surname><given-names>N.</given-names></name></person-group>
<article-title>Participants in the International Multi-disciplinary Consensus Conference on Multimodality, M. Monitoring inflammation (including fever) in acute brain injury</article-title>
<source>Neurocrit. Care</source>
<year>2014</year>
<volume>21</volume>
<fpage>S177</fpage>
<lpage>S186</lpage>
<pub-id pub-id-type="doi">10.1007/s12028-014-0038-0</pub-id>
<pub-id pub-id-type="pmid">25315974</pub-id></element-citation></ref><ref id="B9-ijms-17-00497"><label>9.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xu</surname><given-names>H.L.</given-names></name><name><surname>Garcia</surname><given-names>M.</given-names></name><name><surname>Testai</surname><given-names>F.</given-names></name><name><surname>Vetri</surname><given-names>F.</given-names></name><name><surname>Barabanova</surname><given-names>A.</given-names></name><name><surname>Pelligrino</surname><given-names>D.A.</given-names></name><name><surname>Paisansathan</surname><given-names>C.</given-names></name></person-group>
<article-title>Pharmacologic blockade of vascular adhesion protein-1 lessens neurologic dysfunction in rats subjected to subarachnoid hemorrhage</article-title>
<source>Brain Res.</source>
<year>2014</year>
<volume>1586</volume>
<fpage>83</fpage>
<lpage>89</lpage>
<pub-id pub-id-type="doi">10.1016/j.brainres.2014.08.036</pub-id>
<pub-id pub-id-type="pmid">25175836</pub-id></element-citation></ref><ref id="B10-ijms-17-00497"><label>10.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fisher</surname><given-names>C.M.</given-names></name><name><surname>Kistler</surname><given-names>J.P.</given-names></name><name><surname>Davis</surname><given-names>J.M.</given-names></name></person-group>
<article-title>Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning</article-title>
<source>Neurosurgery</source>
<year>1980</year>
<volume>6</volume>
<fpage>1</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1227/00006123-198001000-00001</pub-id>
<pub-id pub-id-type="pmid">7354892</pub-id></element-citation></ref><ref id="B11-ijms-17-00497"><label>11.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hijdra</surname><given-names>A.</given-names></name><name><surname>van Gijn</surname><given-names>J.</given-names></name><name><surname>Nagelkerke</surname><given-names>N.J.</given-names></name><name><surname>Vermeulen</surname><given-names>M.</given-names></name><name><surname>van Crevel</surname><given-names>H.</given-names></name></person-group>
<article-title>Prediction of delayed cerebral ischemia, rebleeding, and outcome after aneurysmal subarachnoid hemorrhage</article-title>
<source>Stroke J. Cereb. Circ.</source>
<year>1988</year>
<volume>19</volume>
<fpage>1250</fpage>
<lpage>1256</lpage>
<pub-id pub-id-type="doi">10.1161/01.STR.19.10.1250</pub-id>
</element-citation></ref><ref id="B12-ijms-17-00497"><label>12.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pradilla</surname><given-names>G.</given-names></name><name><surname>Chaichana</surname><given-names>K.L.</given-names></name><name><surname>Hoang</surname><given-names>S.</given-names></name><name><surname>Huang</surname><given-names>J.</given-names></name><name><surname>Tamargo</surname><given-names>R.J.</given-names></name></person-group>
<article-title>Inflammation and cerebral vasospasm after subarachnoid hemorrhage</article-title>
<source>Neurosurg. Clin. N. Am.</source>
<year>2010</year>
<volume>21</volume>
<fpage>365</fpage>
<lpage>379</lpage>
<pub-id pub-id-type="doi">10.1016/j.nec.2009.10.008</pub-id>
<pub-id pub-id-type="pmid">20380976</pub-id></element-citation></ref><ref id="B13-ijms-17-00497"><label>13.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ascenzi</surname><given-names>P.</given-names></name><name><surname>Bocedi</surname><given-names>A.</given-names></name><name><surname>Visca</surname><given-names>P.</given-names></name><name><surname>Altruda</surname><given-names>F.</given-names></name><name><surname>Tolosano</surname><given-names>E.</given-names></name><name><surname>Beringhelli</surname><given-names>T.</given-names></name><name><surname>Fasano</surname><given-names>M.</given-names></name></person-group>
<article-title>Hemoglobin and heme scavenging</article-title>
<source>IUBMB Life</source>
<year>2005</year>
<volume>57</volume>
<fpage>749</fpage>
<lpage>759</lpage>
<pub-id pub-id-type="doi">10.1080/15216540500380871</pub-id>
<pub-id pub-id-type="pmid">16511968</pub-id></element-citation></ref><ref id="B14-ijms-17-00497"><label>14.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nozaki</surname><given-names>K.</given-names></name><name><surname>Okamoto</surname><given-names>S.</given-names></name><name><surname>Yanamoto</surname><given-names>H.</given-names></name><name><surname>Kikuchi</surname><given-names>H.</given-names></name></person-group>
<article-title>Red blood cells are essential for late vasospasm following experimentally induced subarachnoid hemorrhage in dogs</article-title>
<source>Neurol. Medico Chir.</source>
<year>1990</year>
<volume>30</volume>
<fpage>10</fpage>
<lpage>15</lpage>
<pub-id pub-id-type="doi">10.2176/nmc.30.10</pub-id>
</element-citation></ref><ref id="B15-ijms-17-00497"><label>15.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Macdonald</surname><given-names>R.L.</given-names></name><name><surname>Marton</surname><given-names>L.S.</given-names></name><name><surname>Andrus</surname><given-names>P.K.</given-names></name><name><surname>Hall</surname><given-names>E.D.</given-names></name><name><surname>Johns</surname><given-names>L.</given-names></name><name><surname>Sajdak</surname><given-names>M.</given-names></name></person-group>
<article-title>Time course of production of hydroxyl free radical after subarachnoid hemorrhage in dogs</article-title>
<source>Life Sci.</source>
<year>2004</year>
<volume>75</volume>
<fpage>979</fpage>
<lpage>989</lpage>
<pub-id pub-id-type="doi">10.1016/j.lfs.2004.02.010</pub-id>
<pub-id pub-id-type="pmid">15193958</pub-id></element-citation></ref><ref id="B16-ijms-17-00497"><label>16.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hailer</surname><given-names>N.P.</given-names></name><name><surname>Bechmann</surname><given-names>I.</given-names></name><name><surname>Heizmann</surname><given-names>S.</given-names></name><name><surname>Nitsch</surname><given-names>R.</given-names></name></person-group>
<article-title>Adhesion molecule expression on phagocytic microglial cells following anterograde degeneration of perforant path axons</article-title>
<source>Hippocampus</source>
<year>1997</year>
<volume>7</volume>
<fpage>341</fpage>
<lpage>349</lpage>
<pub-id pub-id-type="doi">10.1002/(SICI)1098-1063(1997)7:3&#x0003c;341::AID-HIPO8&#x0003e;3.0.CO;2-N</pub-id>
<pub-id pub-id-type="pmid">9228530</pub-id></element-citation></ref><ref id="B17-ijms-17-00497"><label>17.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gallia</surname><given-names>G.L.</given-names></name><name><surname>Tamargo</surname><given-names>R.J.</given-names></name></person-group>
<article-title>Leukocyte-endothelial cell interactions in chronic vasospasm after subarachnoid hemorrhage</article-title>
<source>Neurol. Res.</source>
<year>2006</year>
<volume>28</volume>
<fpage>750</fpage>
<lpage>758</lpage>
<pub-id pub-id-type="doi">10.1179/016164106X152025</pub-id>
<pub-id pub-id-type="pmid">17164038</pub-id></element-citation></ref><ref id="B18-ijms-17-00497"><label>18.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dietrich</surname><given-names>H.H.</given-names></name><name><surname>Dacey</surname><given-names>R.G.</given-names><suffix>Jr.</suffix></name></person-group>
<article-title>Molecular keys to the problems of cerebral vasospasm</article-title>
<source>Neurosurgery</source>
<year>2000</year>
<volume>46</volume>
<fpage>517</fpage>
<lpage>530</lpage>
<pub-id pub-id-type="doi">10.1097/00006123-200003000-00001</pub-id>
<pub-id pub-id-type="pmid">10719847</pub-id></element-citation></ref><ref id="B19-ijms-17-00497"><label>19.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pellettieri</surname><given-names>L.</given-names></name><name><surname>Nilsson</surname><given-names>B.</given-names></name><name><surname>Carlsson</surname><given-names>C.A.</given-names></name><name><surname>Nilsson</surname><given-names>U.</given-names></name></person-group>
<article-title>Serum immunocomplexes in patients with subarachnoid hemorrhage</article-title>
<source>Neurosurgery</source>
<year>1986</year>
<volume>19</volume>
<fpage>767</fpage>
<lpage>771</lpage>
<pub-id pub-id-type="doi">10.1227/00006123-198611000-00008</pub-id>
<pub-id pub-id-type="pmid">3785623</pub-id></element-citation></ref><ref id="B20-ijms-17-00497"><label>20.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kasuya</surname><given-names>H.</given-names></name><name><surname>Shimizu</surname><given-names>T.</given-names></name></person-group>
<article-title>Activated complement components C3a and C4a in cerebrospinal fluid and plasma following subarachnoid hemorrhage</article-title>
<source>J. Neurosurg.</source>
<year>1989</year>
<volume>71</volume>
<fpage>741</fpage>
<lpage>746</lpage>
<pub-id pub-id-type="doi">10.3171/jns.1989.71.5.0741</pub-id>
<pub-id pub-id-type="pmid">2809729</pub-id></element-citation></ref><ref id="B21-ijms-17-00497"><label>21.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sercombe</surname><given-names>R.</given-names></name><name><surname>Dinh</surname><given-names>Y.R.</given-names></name><name><surname>Gomis</surname><given-names>P.</given-names></name></person-group>
<article-title>Cerebrovascular inflammation following subarachnoid hemorrhage</article-title>
<source>Jpn. J. Pharm.</source>
<year>2002</year>
<volume>88</volume>
<fpage>227</fpage>
<lpage>249</lpage>
<pub-id pub-id-type="doi">10.1254/jjp.88.227</pub-id>
</element-citation></ref><ref id="B22-ijms-17-00497"><label>22.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hendryk</surname><given-names>S.</given-names></name><name><surname>Jarzab</surname><given-names>B.</given-names></name><name><surname>Josko</surname><given-names>J.</given-names></name></person-group>
<article-title>Increase of the IL-1&#x003b2; and IL-6 levels in CSF in patients with vasospasm following aneurysmal SAH</article-title>
<source>Neuroendocrinol. Lett.</source>
<year>2004</year>
<volume>25</volume>
<fpage>141</fpage>
<lpage>147</lpage>
<pub-id pub-id-type="pmid">15159698</pub-id></element-citation></ref><ref id="B23-ijms-17-00497"><label>23.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mathiesen</surname><given-names>T.</given-names></name><name><surname>Andersson</surname><given-names>B.</given-names></name><name><surname>Loftenius</surname><given-names>A.</given-names></name><name><surname>von Holst</surname><given-names>H.</given-names></name></person-group>
<article-title>Increased interleukin-6 levels in cerebrospinal fluid following subarachnoid hemorrhage</article-title>
<source>J. Neurosurg.</source>
<year>1993</year>
<volume>78</volume>
<fpage>562</fpage>
<lpage>567</lpage>
<pub-id pub-id-type="doi">10.3171/jns.1993.78.4.0562</pub-id>
<pub-id pub-id-type="pmid">8450329</pub-id></element-citation></ref><ref id="B24-ijms-17-00497"><label>24.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kikuchi</surname><given-names>T.</given-names></name><name><surname>Okuda</surname><given-names>Y.</given-names></name><name><surname>Kaito</surname><given-names>N.</given-names></name><name><surname>Abe</surname><given-names>T.</given-names></name></person-group>
<article-title>Cytokine production in cerebrospinal fluid after subarachnoid haemorrhage</article-title>
<source>Neurol. Res.</source>
<year>1995</year>
<volume>17</volume>
<fpage>106</fpage>
<lpage>108</lpage>
<pub-id pub-id-type="pmid">7609845</pub-id></element-citation></ref><ref id="B25-ijms-17-00497"><label>25.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vikman</surname><given-names>P.</given-names></name><name><surname>Beg</surname><given-names>S.</given-names></name><name><surname>Khurana</surname><given-names>T.S.</given-names></name><name><surname>Hansen-Schwartz</surname><given-names>J.</given-names></name><name><surname>Edvinsson</surname><given-names>L.</given-names></name></person-group>
<article-title>Gene expression and molecular changes in cerebral arteries following subarachnoid hemorrhage in the rat</article-title>
<source>J. Neurosurg.</source>
<year>2006</year>
<volume>105</volume>
<fpage>438</fpage>
<lpage>444</lpage>
<pub-id pub-id-type="doi">10.3171/jns.2006.105.3.438</pub-id>
<pub-id pub-id-type="pmid">16961140</pub-id></element-citation></ref><ref id="B26-ijms-17-00497"><label>26.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sozen</surname><given-names>T.</given-names></name><name><surname>Tsuchiyama</surname><given-names>R.</given-names></name><name><surname>Hasegawa</surname><given-names>Y.</given-names></name><name><surname>Suzuki</surname><given-names>H.</given-names></name><name><surname>Jadhav</surname><given-names>V.</given-names></name><name><surname>Nishizawa</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>J.H.</given-names></name></person-group>
<article-title>Immunological response in early brain injury after SAH</article-title>
<source>Acta Neurochir. Suppl.</source>
<year>2011</year>
<volume>110</volume>
<fpage>57</fpage>
<lpage>61</lpage>
<pub-id pub-id-type="pmid">21116915</pub-id></element-citation></ref><ref id="B27-ijms-17-00497"><label>27.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chaichana</surname><given-names>K.L.</given-names></name><name><surname>Pradilla</surname><given-names>G.</given-names></name><name><surname>Huang</surname><given-names>J.</given-names></name><name><surname>Tamargo</surname><given-names>R.J.</given-names></name></person-group>
<article-title>Role of inflammation (leukocyte-endothelial cell interactions) in vasospasm after subarachnoid hemorrhage</article-title>
<source>World Neurosurg.</source>
<year>2010</year>
<volume>73</volume>
<fpage>22</fpage>
<lpage>41</lpage>
<pub-id pub-id-type="doi">10.1016/j.surneu.2009.05.027</pub-id>
<pub-id pub-id-type="pmid">20452866</pub-id></element-citation></ref><ref id="B28-ijms-17-00497"><label>28.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sarrafzadeh</surname><given-names>A.</given-names></name><name><surname>Schlenk</surname><given-names>F.</given-names></name><name><surname>Gericke</surname><given-names>C.</given-names></name><name><surname>Vajkoczy</surname><given-names>P.</given-names></name></person-group>
<article-title>Relevance of cerebral interleukin-6 after aneurysmal subarachnoid hemorrhage</article-title>
<source>Neurocrit. Care</source>
<year>2010</year>
<volume>13</volume>
<fpage>339</fpage>
<lpage>346</lpage>
<pub-id pub-id-type="doi">10.1007/s12028-010-9432-4</pub-id>
<pub-id pub-id-type="pmid">20725805</pub-id></element-citation></ref><ref id="B29-ijms-17-00497"><label>29.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schneider</surname><given-names>U.C.</given-names></name><name><surname>Davids</surname><given-names>A.M.</given-names></name><name><surname>Brandenburg</surname><given-names>S.</given-names></name><name><surname>Muller</surname><given-names>A.</given-names></name><name><surname>Elke</surname><given-names>A.</given-names></name><name><surname>Magrini</surname><given-names>S.</given-names></name><name><surname>Atangana</surname><given-names>E.</given-names></name><name><surname>Turkowski</surname><given-names>K.</given-names></name><name><surname>Finger</surname><given-names>T.</given-names></name><name><surname>Gutenberg</surname><given-names>A.</given-names></name><etal/></person-group>
<article-title>Microglia inflict delayed brain injury after subarachnoid hemorrhage</article-title>
<source>Acta Neuropathol.</source>
<year>2015</year>
<volume>130</volume>
<fpage>215</fpage>
<lpage>231</lpage>
<pub-id pub-id-type="doi">10.1007/s00401-015-1440-1</pub-id>
<pub-id pub-id-type="pmid">25956409</pub-id></element-citation></ref><ref id="B30-ijms-17-00497"><label>30.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hughes</surname><given-names>J.T.</given-names></name><name><surname>Schianchi</surname><given-names>P.M.</given-names></name></person-group>
<article-title>Cerebral artery spasm. A histological study at necropsy of the blood vessels in cases of subarachnoid hemorrhage</article-title>
<source>J. Neurosurg.</source>
<year>1978</year>
<volume>48</volume>
<fpage>515</fpage>
<lpage>525</lpage>
<pub-id pub-id-type="doi">10.3171/jns.1978.48.4.0515</pub-id>
<pub-id pub-id-type="pmid">632876</pub-id></element-citation></ref><ref id="B31-ijms-17-00497"><label>31.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chyatte</surname><given-names>D.</given-names></name><name><surname>Bruno</surname><given-names>G.</given-names></name><name><surname>Desai</surname><given-names>S.</given-names></name><name><surname>Todor</surname><given-names>D.R.</given-names></name></person-group>
<article-title>Inflammation and intracranial aneurysms</article-title>
<source>Neurosurgery</source>
<year>1999</year>
<volume>45</volume>
<fpage>1137</fpage>
<lpage>1146</lpage>
<pub-id pub-id-type="doi">10.1097/00006123-199911000-00024</pub-id>
<pub-id pub-id-type="pmid">10549930</pub-id></element-citation></ref><ref id="B32-ijms-17-00497"><label>32.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Uekawa</surname><given-names>K.</given-names></name><name><surname>Hasegawa</surname><given-names>Y.</given-names></name><name><surname>Ma</surname><given-names>M.</given-names></name><name><surname>Nakagawa</surname><given-names>T.</given-names></name><name><surname>Katayama</surname><given-names>T.</given-names></name><name><surname>Sueta</surname><given-names>D.</given-names></name><name><surname>Toyama</surname><given-names>K.</given-names></name><name><surname>Kataoka</surname><given-names>K.</given-names></name><name><surname>Koibuchi</surname><given-names>N.</given-names></name><name><surname>Kawano</surname><given-names>T.</given-names></name><etal/></person-group>
<article-title>Rosuvastatin ameliorates early brain injury after subarachnoid hemorrhage via suppression of superoxide formation and nuclear factor-&#x003ba;B activation in rats</article-title>
<source>J. Stroke Cerebrovasc. Dis.</source>
<year>2014</year>
<volume>23</volume>
<fpage>1429</fpage>
<lpage>1439</lpage>
<pub-id pub-id-type="doi">10.1016/j.jstrokecerebrovasdis.2013.12.004</pub-id>
<pub-id pub-id-type="pmid">24529602</pub-id></element-citation></ref><ref id="B33-ijms-17-00497"><label>33.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X.S.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Wu</surname><given-names>Q.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>C.X.</given-names></name><name><surname>Xie</surname><given-names>G.B.</given-names></name><name><surname>Zhou</surname><given-names>X.M.</given-names></name><name><surname>Shi</surname><given-names>J.X.</given-names></name><name><surname>Zhou</surname><given-names>M.L.</given-names></name></person-group>
<article-title>Astaxanthin offers neuroprotection and reduces neuroinflammation in experimental subarachnoid hemorrhage</article-title>
<source>J. Surg. Res.</source>
<year>2014</year>
<volume>192</volume>
<fpage>206</fpage>
<lpage>213</lpage>
<pub-id pub-id-type="doi">10.1016/j.jss.2014.05.029</pub-id>
<pub-id pub-id-type="pmid">24948541</pub-id></element-citation></ref><ref id="B34-ijms-17-00497"><label>34.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McGirt</surname><given-names>M.J.</given-names></name><name><surname>Lynch</surname><given-names>J.R.</given-names></name><name><surname>Blessing</surname><given-names>R.</given-names></name><name><surname>Warner</surname><given-names>D.S.</given-names></name><name><surname>Friedman</surname><given-names>A.H.</given-names></name><name><surname>Laskowitz</surname><given-names>D.T.</given-names></name></person-group>
<article-title>Serum von willebrand factor, matrix metalloproteinase-9, and vascular endothelial growth factor levels predict the onset of cerebral vasospasm after aneurysmal subarachnoid hemorrhage</article-title>
<source>Neurosurgery</source>
<year>2002</year>
<volume>51</volume>
<fpage>1128</fpage>
<lpage>1134</lpage>
<comment>discussion 1125&#x02013;1134</comment>
<pub-id pub-id-type="doi">10.1097/00006123-200211000-00005</pub-id>
<pub-id pub-id-type="pmid">12383357</pub-id></element-citation></ref><ref id="B35-ijms-17-00497"><label>35.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chou</surname><given-names>S.H.</given-names></name><name><surname>Feske</surname><given-names>S.K.</given-names></name><name><surname>Simmons</surname><given-names>S.L.</given-names></name><name><surname>Konigsberg</surname><given-names>R.G.</given-names></name><name><surname>Orzell</surname><given-names>S.C.</given-names></name><name><surname>Marckmann</surname><given-names>A.</given-names></name><name><surname>Bourget</surname><given-names>G.</given-names></name><name><surname>Bauer</surname><given-names>D.J.</given-names></name><name><surname>de Jager</surname><given-names>P.L.</given-names></name><name><surname>Du</surname><given-names>R.</given-names></name><etal/></person-group>
<article-title>Elevated peripheral neutrophils and matrix metalloproteinase 9 as biomarkers of functional outco me following subarachnoid hemorrhage</article-title>
<source>Transl. Stroke Res.</source>
<year>2011</year>
<volume>2</volume>
<fpage>600</fpage>
<lpage>607</lpage>
<pub-id pub-id-type="doi">10.1007/s12975-011-0117-x</pub-id>
<pub-id pub-id-type="pmid">22207885</pub-id></element-citation></ref><ref id="B36-ijms-17-00497"><label>36.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Feiler</surname><given-names>S.</given-names></name><name><surname>Plesnila</surname><given-names>N.</given-names></name><name><surname>Thal</surname><given-names>S.C.</given-names></name><name><surname>Zausinger</surname><given-names>S.</given-names></name><name><surname>Scholler</surname><given-names>K.</given-names></name></person-group>
<article-title>Contribution of matrix metalloproteinase-9 to cerebral edema and functional outcome following experimental subarachnoid hemorrhage</article-title>
<source>Cerebrovasc. Dis.</source>
<year>2011</year>
<volume>32</volume>
<fpage>289</fpage>
<lpage>295</lpage>
<pub-id pub-id-type="doi">10.1159/000328248</pub-id>
<pub-id pub-id-type="pmid">21912109</pub-id></element-citation></ref><ref id="B37-ijms-17-00497"><label>37.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhao</surname><given-names>X.</given-names></name><name><surname>Song</surname><given-names>S.</given-names></name><name><surname>Sun</surname><given-names>G.</given-names></name><name><surname>Strong</surname><given-names>R.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Grotta</surname><given-names>J.C.</given-names></name><name><surname>Aronowski</surname><given-names>J.</given-names></name></person-group>
<article-title>Neuroprotective role of haptoglobin after intracerebral hemorrhage</article-title>
<source>J. Neurosci. Off. J. Soc. Neurosc.</source>
<year>2009</year>
<volume>29</volume>
<fpage>15819</fpage>
<lpage>15827</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.3776-09.2009</pub-id>
<pub-id pub-id-type="pmid">20016097</pub-id></element-citation></ref><ref id="B38-ijms-17-00497"><label>38.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fassbender</surname><given-names>K.</given-names></name><name><surname>Hodapp</surname><given-names>B.</given-names></name><name><surname>Rossol</surname><given-names>S.</given-names></name><name><surname>Bertsch</surname><given-names>T.</given-names></name><name><surname>Schmeck</surname><given-names>J.</given-names></name><name><surname>Schutt</surname><given-names>S.</given-names></name><name><surname>Fritzinger</surname><given-names>M.</given-names></name><name><surname>Horn</surname><given-names>P.</given-names></name><name><surname>Vajkoczy</surname><given-names>P.</given-names></name><name><surname>Kreisel</surname><given-names>S.</given-names></name><etal/></person-group>
<article-title>Inflammatory cytokines in subarachnoid haemorrhage: Association with abnormal blood flow velocities in basal cerebral arteries</article-title>
<source>J. Neurol. Neurosurg. Psychiatry</source>
<year>2001</year>
<volume>70</volume>
<fpage>534</fpage>
<lpage>537</lpage>
<pub-id pub-id-type="doi">10.1136/jnnp.70.4.534</pub-id>
<pub-id pub-id-type="pmid">11254783</pub-id></element-citation></ref><ref id="B39-ijms-17-00497"><label>39.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Iliff</surname><given-names>J.J.</given-names></name><name><surname>Chen</surname><given-names>M.J.</given-names></name><name><surname>Plog</surname><given-names>B.A.</given-names></name><name><surname>Zeppenfeld</surname><given-names>D.M.</given-names></name><name><surname>Soltero</surname><given-names>M.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Singh</surname><given-names>I.</given-names></name><name><surname>Deane</surname><given-names>R.</given-names></name><name><surname>Nedergaard</surname><given-names>M.</given-names></name></person-group>
<article-title>Impairment of glymphatic pathway function promotes tau pathology after traumatic brain injury</article-title>
<source>J. Neurosci. Off. J. Soc. Neurosc.</source>
<year>2014</year>
<volume>34</volume>
<fpage>16180</fpage>
<lpage>16193</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.3020-14.2014</pub-id>
<pub-id pub-id-type="pmid">25471560</pub-id></element-citation></ref><ref id="B40-ijms-17-00497"><label>40.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Iliff</surname><given-names>J.J.</given-names></name><name><surname>Nedergaard</surname><given-names>M.</given-names></name></person-group>
<article-title>Is there a cerebral lymphatic system?</article-title>
<source>Stroke</source>
<year>2013</year>
<volume>44</volume>
<fpage>S93</fpage>
<lpage>S95</lpage>
<pub-id pub-id-type="doi">10.1161/STROKEAHA.112.678698</pub-id>
<pub-id pub-id-type="pmid">23709744</pub-id></element-citation></ref><ref id="B41-ijms-17-00497"><label>41.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Borsody</surname><given-names>M.</given-names></name><name><surname>Burke</surname><given-names>A.</given-names></name><name><surname>Coplin</surname><given-names>W.</given-names></name><name><surname>Miller-Lotan</surname><given-names>R.</given-names></name><name><surname>Levy</surname><given-names>A.</given-names></name></person-group>
<article-title>Haptoglobin and the development of cerebral artery vasospasm after subarachnoid hemorrhage</article-title>
<source>Neurology</source>
<year>2006</year>
<volume>66</volume>
<fpage>634</fpage>
<lpage>640</lpage>
<pub-id pub-id-type="doi">10.1212/01.wnl.0000200781.62172.1d</pub-id>
<pub-id pub-id-type="pmid">16436647</pub-id></element-citation></ref><ref id="B42-ijms-17-00497"><label>42.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wu</surname><given-names>C.T.</given-names></name><name><surname>Wong</surname><given-names>C.S.</given-names></name><name><surname>Yeh</surname><given-names>C.C.</given-names></name><name><surname>Borel</surname><given-names>C.O.</given-names></name></person-group>
<article-title>Treatment of cerebral vasospasm after subarachnoid hemorrhage&#x02014;A review</article-title>
<source>Acta Anaesthesiol. Taiwan</source>
<year>2004</year>
<volume>42</volume>
<fpage>215</fpage>
<lpage>222</lpage>
<pub-id pub-id-type="pmid">15679131</pub-id></element-citation></ref><ref id="B43-ijms-17-00497"><label>43.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rabinstein</surname><given-names>A.A.</given-names></name><name><surname>Weigand</surname><given-names>S.</given-names></name><name><surname>Atkinson</surname><given-names>J.L.</given-names></name><name><surname>Wijdicks</surname><given-names>E.F.</given-names></name></person-group>
<article-title>Patterns of cerebral infarction in aneurysmal subarachnoid hemorrhage</article-title>
<source>Stroke</source>
<year>2005</year>
<volume>36</volume>
<fpage>992</fpage>
<lpage>997</lpage>
<pub-id pub-id-type="doi">10.1161/01.STR.0000163090.59350.5a</pub-id>
<pub-id pub-id-type="pmid">15831836</pub-id></element-citation></ref><ref id="B44-ijms-17-00497"><label>44.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ma</surname><given-names>J.</given-names></name><name><surname>Huang</surname><given-names>S.</given-names></name><name><surname>Ma</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>You</surname><given-names>C.</given-names></name></person-group>
<article-title>Endothelin-receptor antagonists for aneurysmal subarachnoid hemorrhage: An updated meta-analysis of randomized controlled trials</article-title>
<source>Crit. Care</source>
<year>2012</year>
<volume>16</volume>
<fpage>R198</fpage>
<pub-id pub-id-type="doi">10.1186/cc11686</pub-id>
<pub-id pub-id-type="pmid">23078672</pub-id></element-citation></ref><ref id="B45-ijms-17-00497"><label>45.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Konczalla</surname><given-names>J.</given-names></name><name><surname>Kashefiolasl</surname><given-names>S.</given-names></name><name><surname>Brawanski</surname><given-names>N.</given-names></name><name><surname>Lescher</surname><given-names>S.</given-names></name><name><surname>Senft</surname><given-names>C.</given-names></name><name><surname>Platz</surname><given-names>J.</given-names></name><name><surname>Seifert</surname><given-names>V.</given-names></name></person-group>
<article-title>Cerebral vasospasm and delayed cerebral infarctions in 225 patients with non-aneurysmal subarachnoid hemorrhage: The underestimated risk of fisher 3 blood distribution</article-title>
<source>J. Neurointerv. Surg.</source>
<year>2016</year>
<pub-id pub-id-type="doi">10.1136/neurintsurg-2015-012153</pub-id>
<pub-id pub-id-type="pmid">26847333</pub-id></element-citation></ref><ref id="B46-ijms-17-00497"><label>46.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bederson</surname><given-names>J.B.</given-names></name><name><surname>Levy</surname><given-names>A.L.</given-names></name><name><surname>Ding</surname><given-names>W.H.</given-names></name><name><surname>Kahn</surname><given-names>R.</given-names></name><name><surname>DiPerna</surname><given-names>C.A.</given-names></name><name><surname>Jenkins</surname><given-names>A.L.</given-names><suffix>3rd</suffix></name><name><surname>Vallabhajosyula</surname><given-names>P.</given-names></name></person-group>
<article-title>Acute vasoconstriction after subarachnoid hemorrhage</article-title>
<source>Neurosurgery</source>
<year>1998</year>
<volume>42</volume>
<fpage>352</fpage>
<lpage>360</lpage>
<pub-id pub-id-type="doi">10.1097/00006123-199802000-00091</pub-id>
<pub-id pub-id-type="pmid">9482187</pub-id></element-citation></ref><ref id="B47-ijms-17-00497"><label>47.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kassell</surname><given-names>N.F.</given-names></name><name><surname>Sasaki</surname><given-names>T.</given-names></name><name><surname>Colohan</surname><given-names>A.R.</given-names></name><name><surname>Nazar</surname><given-names>G.</given-names></name></person-group>
<article-title>Cerebral vasospasm following aneurysmal subarachnoid hemorrhage</article-title>
<source>Stroke</source>
<year>1985</year>
<volume>16</volume>
<fpage>562</fpage>
<lpage>572</lpage>
<pub-id pub-id-type="doi">10.1161/01.STR.16.4.562</pub-id>
<pub-id pub-id-type="pmid">3895589</pub-id></element-citation></ref><ref id="B48-ijms-17-00497"><label>48.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Provencio</surname><given-names>J.J.</given-names></name><name><surname>Vora</surname><given-names>N.</given-names></name></person-group>
<article-title>Subarachnoid hemorrhage and inflammation: Bench to bedside and back</article-title>
<source>Semin. Neurol.</source>
<year>2005</year>
<volume>25</volume>
<fpage>435</fpage>
<lpage>444</lpage>
<pub-id pub-id-type="doi">10.1055/s-2005-923537</pub-id>
<pub-id pub-id-type="pmid">16341999</pub-id></element-citation></ref><ref id="B49-ijms-17-00497"><label>49.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Altay</surname><given-names>T.</given-names></name><name><surname>Smithason</surname><given-names>S.</given-names></name><name><surname>Volokh</surname><given-names>N.</given-names></name><name><surname>Rasmussen</surname><given-names>P.A.</given-names></name><name><surname>Ransohoff</surname><given-names>R.M.</given-names></name><name><surname>Provencio</surname><given-names>J.J.</given-names></name></person-group>
<article-title>A novel method for subarachnoid hemorrhage to induce vasospasm in mice</article-title>
<source>J. Neurosci. Methods</source>
<year>2009</year>
<volume>183</volume>
<fpage>136</fpage>
<lpage>140</lpage>
<pub-id pub-id-type="doi">10.1016/j.jneumeth.2009.06.027</pub-id>
<pub-id pub-id-type="pmid">19576247</pub-id></element-citation></ref><ref id="B50-ijms-17-00497"><label>50.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lin</surname><given-names>C.L.</given-names></name><name><surname>Calisaneller</surname><given-names>T.</given-names></name><name><surname>Ukita</surname><given-names>N.</given-names></name><name><surname>Dumont</surname><given-names>A.S.</given-names></name><name><surname>Kassell</surname><given-names>N.F.</given-names></name><name><surname>Lee</surname><given-names>K.S.</given-names></name></person-group>
<article-title>A murine model of subarachnoid hemorrhage-induced cerebral vasospasm</article-title>
<source>J. Neurosci. Methods</source>
<year>2003</year>
<volume>123</volume>
<fpage>89</fpage>
<lpage>97</lpage>
<pub-id pub-id-type="doi">10.1016/S0165-0270(02)00344-8</pub-id>
<pub-id pub-id-type="pmid">12581852</pub-id></element-citation></ref><ref id="B51-ijms-17-00497"><label>51.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mesis</surname><given-names>R.G.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Lombard</surname><given-names>F.W.</given-names></name><name><surname>Yates</surname><given-names>R.</given-names></name><name><surname>Vitek</surname><given-names>M.P.</given-names></name><name><surname>Borel</surname><given-names>C.O.</given-names></name><name><surname>Warner</surname><given-names>D.S.</given-names></name><name><surname>Laskowitz</surname><given-names>D.T.</given-names></name></person-group>
<article-title>Dissociation between vasospasm and functional improvement in a murine model of subarachnoid hemorrhage</article-title>
<source>Neurosurg. Focus</source>
<year>2006</year>
<volume>21</volume>
<fpage>E4</fpage>
<pub-id pub-id-type="doi">10.3171/foc.2006.21.3.4</pub-id>
<pub-id pub-id-type="pmid">17029343</pub-id></element-citation></ref><ref id="B52-ijms-17-00497"><label>52.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Parra</surname><given-names>A.</given-names></name><name><surname>McGirt</surname><given-names>M.J.</given-names></name><name><surname>Sheng</surname><given-names>H.</given-names></name><name><surname>Laskowitz</surname><given-names>D.T.</given-names></name><name><surname>Pearlstein</surname><given-names>R.D.</given-names></name><name><surname>Warner</surname><given-names>D.S.</given-names></name></person-group>
<article-title>Mouse model of subarachnoid hemorrhage associated cerebral vasospasm: Methodological analysis</article-title>
<source>Neurol. Res.</source>
<year>2002</year>
<volume>24</volume>
<fpage>510</fpage>
<lpage>516</lpage>
<pub-id pub-id-type="doi">10.1179/016164102101200276</pub-id>
<pub-id pub-id-type="pmid">12117325</pub-id></element-citation></ref><ref id="B53-ijms-17-00497"><label>53.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mori</surname><given-names>K.</given-names></name><name><surname>Fujii</surname><given-names>K.</given-names></name><name><surname>Tomura</surname><given-names>S.</given-names></name><name><surname>Ueno</surname><given-names>H.</given-names></name><name><surname>Wada</surname><given-names>K.</given-names></name><name><surname>Otani</surname><given-names>N.</given-names></name><name><surname>Osada</surname><given-names>H.</given-names></name><name><surname>Tomiyama</surname><given-names>A.</given-names></name></person-group>
<article-title>Canine double hemorrhage model of experimental subarachnoid hemorrhage</article-title>
<source>Acta Neurochir. Suppl.</source>
<year>2015</year>
<volume>120</volume>
<fpage>347</fpage>
<lpage>351</lpage>
<pub-id pub-id-type="pmid">25366650</pub-id></element-citation></ref><ref id="B54-ijms-17-00497"><label>54.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Springborg</surname><given-names>J.B.</given-names></name><name><surname>Moller</surname><given-names>C.</given-names></name><name><surname>Gideon</surname><given-names>P.</given-names></name><name><surname>Jorgensen</surname><given-names>O.S.</given-names></name><name><surname>Juhler</surname><given-names>M.</given-names></name><name><surname>Olsen</surname><given-names>N.V.</given-names></name></person-group>
<article-title>Erythropoietin in patients with aneurysmal subarachnoid haemorrhage: A double blind randomised clinical trial</article-title>
<source>Acta Neurochir.</source>
<year>2007</year>
<volume>149</volume>
<fpage>1089</fpage>
<lpage>1101</lpage>
<pub-id pub-id-type="doi">10.1007/s00701-007-1284-z</pub-id>
<pub-id pub-id-type="pmid">17876497</pub-id></element-citation></ref><ref id="B55-ijms-17-00497"><label>55.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Provencio</surname><given-names>J.J.</given-names></name><name><surname>Fu</surname><given-names>X.</given-names></name><name><surname>Siu</surname><given-names>A.</given-names></name><name><surname>Rasmussen</surname><given-names>P.A.</given-names></name><name><surname>Hazen</surname><given-names>S.L.</given-names></name><name><surname>Ransohoff</surname><given-names>R.M.</given-names></name></person-group>
<article-title>CSF neutrophils are implicated in the development of vasospasm in subarachnoid hemorrhage</article-title>
<source>Neurocrit. Care</source>
<year>2010</year>
<volume>12</volume>
<fpage>244</fpage>
<lpage>251</lpage>
<pub-id pub-id-type="doi">10.1007/s12028-009-9308-7</pub-id>
<pub-id pub-id-type="pmid">19967568</pub-id></element-citation></ref><ref id="B56-ijms-17-00497"><label>56.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Figueiredo</surname><given-names>R.T.</given-names></name><name><surname>Fernandez</surname><given-names>P.L.</given-names></name><name><surname>Mourao-Sa</surname><given-names>D.S.</given-names></name><name><surname>Porto</surname><given-names>B.N.</given-names></name><name><surname>Dutra</surname><given-names>F.F.</given-names></name><name><surname>Alves</surname><given-names>L.S.</given-names></name><name><surname>Oliveira</surname><given-names>M.F.</given-names></name><name><surname>Oliveira</surname><given-names>P.L.</given-names></name><name><surname>Graca-Souza</surname><given-names>A.V.</given-names></name><name><surname>Bozza</surname><given-names>M.T.</given-names></name></person-group>
<article-title>Characterization of heme as activator of toll-like receptor 4</article-title>
<source>J. Biol. Chem.</source>
<year>2007</year>
<volume>282</volume>
<fpage>20221</fpage>
<lpage>20229</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M610737200</pub-id>
<pub-id pub-id-type="pmid">17502383</pub-id></element-citation></ref><ref id="B57-ijms-17-00497"><label>57.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Crowley</surname><given-names>R.W.</given-names></name><name><surname>Medel</surname><given-names>R.</given-names></name><name><surname>Kassell</surname><given-names>N.F.</given-names></name><name><surname>Dumont</surname><given-names>A.S.</given-names></name></person-group>
<article-title>New insights into the causes and therapy of cerebral vasospasm following subarachnoid hemorrhage</article-title>
<source>Drug Discov. Today</source>
<year>2008</year>
<volume>13</volume>
<fpage>254</fpage>
<lpage>260</lpage>
<pub-id pub-id-type="doi">10.1016/j.drudis.2007.11.010</pub-id>
<pub-id pub-id-type="pmid">18342802</pub-id></element-citation></ref><ref id="B58-ijms-17-00497"><label>58.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hanafy</surname><given-names>K.A.</given-names></name></person-group>
<article-title>The role of microglia and the tlr4 pathway in neuronal apoptosis and vasospasm after subarachnoid hemorrhage</article-title>
<source>J. Neuroinflamm.</source>
<year>2013</year>
<volume>10</volume>
<fpage>83</fpage>
<pub-id pub-id-type="doi">10.1186/1742-2094-10-83</pub-id>
<pub-id pub-id-type="pmid">23849248</pub-id></element-citation></ref><ref id="B59-ijms-17-00497"><label>59.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>G.</given-names></name><name><surname>Ghosh</surname><given-names>S.</given-names></name></person-group>
<article-title>Toll-like receptor-mediated NF-&#x003ba;B activation: A phylogenetically conserved paradigm in innate immunity</article-title>
<source>J. Clin. Investig.</source>
<year>2001</year>
<volume>107</volume>
<fpage>13</fpage>
<lpage>19</lpage>
<pub-id pub-id-type="doi">10.1172/JCI11837</pub-id>
<pub-id pub-id-type="pmid">11134172</pub-id></element-citation></ref><ref id="B60-ijms-17-00497"><label>60.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>O'Neill</surname><given-names>L.A.</given-names></name><name><surname>Bowie</surname><given-names>A.G.</given-names></name></person-group>
<article-title>The family of five: Tir-domain-containing adaptors in toll-like receptor signalling</article-title>
<source>Nat. Rev. Immunol.</source>
<year>2007</year>
<volume>7</volume>
<fpage>353</fpage>
<lpage>364</lpage>
<pub-id pub-id-type="doi">10.1038/nri2079</pub-id>
<pub-id pub-id-type="pmid">17457343</pub-id></element-citation></ref><ref id="B61-ijms-17-00497"><label>61.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sun</surname><given-names>X.</given-names></name><name><surname>Ji</surname><given-names>C.</given-names></name><name><surname>Hu</surname><given-names>T.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Chen</surname><given-names>G.</given-names></name></person-group>
<article-title>Tamoxifen as an effective neuroprotectant against early brain injury and learning deficits induced by subarachnoid hemorrhage: Possible involvement of inflammatory signaling</article-title>
<source>J. Neuroinflamm.</source>
<year>2013</year>
<volume>10</volume>
<fpage>157</fpage>
<pub-id pub-id-type="doi">10.1186/1742-2094-10-157</pub-id>
<pub-id pub-id-type="pmid">24373431</pub-id></element-citation></ref><ref id="B62-ijms-17-00497"><label>62.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Al-Khindi</surname><given-names>T.</given-names></name><name><surname>Macdonald</surname><given-names>R.L.</given-names></name><name><surname>Schweizer</surname><given-names>T.A.</given-names></name></person-group>
<article-title>Cognitive and functional outcome after aneurysmal subarachnoid hemorrhage</article-title>
<source>Stroke</source>
<year>2010</year>
<volume>41</volume>
<fpage>e519</fpage>
<lpage>e536</lpage>
<pub-id pub-id-type="doi">10.1161/STROKEAHA.110.581975</pub-id>
<pub-id pub-id-type="pmid">20595669</pub-id></element-citation></ref><ref id="B63-ijms-17-00497"><label>63.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kooijman</surname><given-names>E.</given-names></name><name><surname>Nijboer</surname><given-names>C.H.</given-names></name><name><surname>van Velthoven</surname><given-names>C.T.</given-names></name><name><surname>Mol</surname><given-names>W.</given-names></name><name><surname>Dijkhuizen</surname><given-names>R.M.</given-names></name><name><surname>Kesecioglu</surname><given-names>J.</given-names></name><name><surname>Heijnen</surname><given-names>C.J.</given-names></name></person-group>
<article-title>Long-term functional consequences and ongoing cerebral inflammation after subarachnoid hemorrhage in the rat</article-title>
<source>PLoS ONE</source>
<year>2014</year>
<volume>9</volume>
<elocation-id>497</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0090584</pub-id>
<pub-id pub-id-type="pmid">24603553</pub-id></element-citation></ref><ref id="B64-ijms-17-00497"><label>64.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Franklin</surname><given-names>R.J.</given-names></name><name><surname>Ffrench-Constant</surname><given-names>C.</given-names></name></person-group>
<article-title>Remyelination in the CNS: From biology to therapy</article-title>
<source>Nat. Rev. Neurosci.</source>
<year>2008</year>
<volume>9</volume>
<fpage>839</fpage>
<lpage>855</lpage>
<pub-id pub-id-type="doi">10.1038/nrn2480</pub-id>
<pub-id pub-id-type="pmid">18931697</pub-id></element-citation></ref><ref id="B65-ijms-17-00497"><label>65.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Segovia</surname><given-names>K.N.</given-names></name><name><surname>McClure</surname><given-names>M.</given-names></name><name><surname>Moravec</surname><given-names>M.</given-names></name><name><surname>Luo</surname><given-names>N.L.</given-names></name><name><surname>Wan</surname><given-names>Y.</given-names></name><name><surname>Gong</surname><given-names>X.</given-names></name><name><surname>Riddle</surname><given-names>A.</given-names></name><name><surname>Craig</surname><given-names>A.</given-names></name><name><surname>Struve</surname><given-names>J.</given-names></name><name><surname>Sherman</surname><given-names>L.S.</given-names></name><etal/></person-group>
<article-title>Arrested oligodendrocyte lineage maturation in chronic perinatal white matter injury</article-title>
<source>Ann. Neurol.</source>
<year>2008</year>
<volume>63</volume>
<fpage>520</fpage>
<lpage>530</lpage>
<pub-id pub-id-type="doi">10.1002/ana.21359</pub-id>
<pub-id pub-id-type="pmid">18393269</pub-id></element-citation></ref><ref id="B66-ijms-17-00497"><label>66.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Franklin</surname><given-names>R.J.</given-names></name><name><surname>Kotter</surname><given-names>M.R.</given-names></name></person-group>
<article-title>The biology of cns remyelination: The key to therapeutic advances</article-title>
<source>J. Neurol.</source>
<year>2008</year>
<volume>255</volume>
<issue>Suppl. 1</issue>
<fpage>19</fpage>
<lpage>25</lpage>
<pub-id pub-id-type="doi">10.1007/s00415-008-1004-6</pub-id>
<pub-id pub-id-type="pmid">18317673</pub-id></element-citation></ref><ref id="B67-ijms-17-00497"><label>67.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Buga</surname><given-names>A.M.</given-names></name><name><surname>di Napoli</surname><given-names>M.</given-names></name><name><surname>Popa-Wagner</surname><given-names>A.</given-names></name></person-group>
<article-title>Preclinical models of stroke in aged animals with or without comorbidities: Role of neuroinflammation</article-title>
<source>Biogerontology</source>
<year>2013</year>
<volume>14</volume>
<fpage>651</fpage>
<lpage>662</lpage>
<pub-id pub-id-type="doi">10.1007/s10522-013-9465-0</pub-id>
<pub-id pub-id-type="pmid">24057280</pub-id></element-citation></ref><ref id="B68-ijms-17-00497"><label>68.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Donnelly</surname><given-names>M.K.</given-names></name><name><surname>Crago</surname><given-names>E.A.</given-names></name><name><surname>Conley</surname><given-names>Y.P.</given-names></name><name><surname>Balzer</surname><given-names>J.R.</given-names></name><name><surname>Ren</surname><given-names>D.</given-names></name><name><surname>Ducruet</surname><given-names>A.F.</given-names></name><name><surname>Kochanek</surname><given-names>P.M.</given-names></name><name><surname>Sherwood</surname><given-names>P.R.</given-names></name><name><surname>Poloyac</surname><given-names>S.M.</given-names></name></person-group>
<article-title>20-hete is associated with unfavorable outcomes in subarachnoid hemorrhage patients</article-title>
<source>J. Cereb. Blood Flow Metab.</source>
<year>2015</year>
<volume>35</volume>
<fpage>1515</fpage>
<lpage>1512</lpage>
<pub-id pub-id-type="doi">10.1038/jcbfm.2015.75</pub-id>
<pub-id pub-id-type="pmid">25920956</pub-id></element-citation></ref><ref id="B69-ijms-17-00497"><label>69.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Donnelly</surname><given-names>M.K.</given-names></name><name><surname>Conley</surname><given-names>Y.P.</given-names></name><name><surname>Crago</surname><given-names>E.A.</given-names></name><name><surname>Ren</surname><given-names>D.</given-names></name><name><surname>Sherwood</surname><given-names>P.R.</given-names></name><name><surname>Balzer</surname><given-names>J.R.</given-names></name><name><surname>Poloyac</surname><given-names>S.M.</given-names></name></person-group>
<article-title>Genetic markers in the EET metabolic pathway are associated with outcomes in patients with aneurysmal subarachnoid hemorrhage</article-title>
<source>J. Cereb. Blood Flow Metab.</source>
<year>2015</year>
<volume>35</volume>
<fpage>267</fpage>
<lpage>276</lpage>
<pub-id pub-id-type="doi">10.1038/jcbfm.2014.195</pub-id>
<pub-id pub-id-type="pmid">25388680</pub-id></element-citation></ref><ref id="B70-ijms-17-00497"><label>70.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sathyan</surname><given-names>S.</given-names></name><name><surname>Koshy</surname><given-names>L.V.</given-names></name><name><surname>Balan</surname><given-names>S.</given-names></name><name><surname>Easwer</surname><given-names>H.V.</given-names></name><name><surname>Premkumar</surname><given-names>S.</given-names></name><name><surname>Nair</surname><given-names>S.</given-names></name><name><surname>Bhattacharya</surname><given-names>R.N.</given-names></name><name><surname>Alapatt</surname><given-names>J.P.</given-names></name><name><surname>Banerjee</surname><given-names>M.</given-names></name></person-group>
<article-title>Association of versican (<italic>VCAN</italic>) gene polymorphisms rs251124 and rs2287926 (g428d), with intracranial aneurysm</article-title>
<source>Meta Gene</source>
<year>2014</year>
<volume>2</volume>
<fpage>651</fpage>
<lpage>660</lpage>
<pub-id pub-id-type="doi">10.1016/j.mgene.2014.07.001</pub-id>
<pub-id pub-id-type="pmid">25606449</pub-id></element-citation></ref><ref id="B71-ijms-17-00497"><label>71.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McDowell</surname><given-names>M.M.</given-names></name><name><surname>Ducruet</surname><given-names>A.F.</given-names></name></person-group>
<article-title>The genetics of aneurysms: A complex pathophysiology requiring complex analysis</article-title>
<source>World Neurosurg.</source>
<year>2015</year>
<volume>83</volume>
<fpage>280</fpage>
<lpage>281</lpage>
<pub-id pub-id-type="doi">10.1016/j.wneu.2015.01.002</pub-id>
<pub-id pub-id-type="pmid">25615901</pub-id></element-citation></ref><ref id="B72-ijms-17-00497"><label>72.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Waters</surname><given-names>R.J.</given-names></name><name><surname>Nicoll</surname><given-names>J.A.</given-names></name></person-group>
<article-title>Genetic influences on outcome following acute neurological insults</article-title>
<source>Curr. Opin. Crit. Care</source>
<year>2005</year>
<volume>11</volume>
<fpage>105</fpage>
<lpage>110</lpage>
<pub-id pub-id-type="doi">10.1097/01.ccx.0000155354.78617.91</pub-id>
<pub-id pub-id-type="pmid">15758588</pub-id></element-citation></ref><ref id="B73-ijms-17-00497"><label>73.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Leclerc</surname><given-names>J.L.</given-names></name><name><surname>Blackburn</surname><given-names>S.</given-names></name><name><surname>Neal</surname><given-names>D.</given-names></name><name><surname>Mendez</surname><given-names>N.V.</given-names></name><name><surname>Wharton</surname><given-names>J.A.</given-names></name><name><surname>Waters</surname><given-names>M.F.</given-names></name><name><surname>Dore</surname><given-names>S.</given-names></name></person-group>
<article-title>Haptoglobin phenotype predicts the development of focal and global cerebral vasospasm and may influence outcomes after aneurysmal subarachnoid hemorrhage</article-title>
<source>Proc. Natl. Acad. Sci. USA</source>
<year>2015</year>
<volume>112</volume>
<fpage>1155</fpage>
<lpage>1160</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1412833112</pub-id>
<pub-id pub-id-type="pmid">25583472</pub-id></element-citation></ref><ref id="B74-ijms-17-00497"><label>74.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Alfieri</surname><given-names>A.</given-names></name><name><surname>Unterhuber</surname><given-names>V.</given-names></name><name><surname>Pircher</surname><given-names>M.</given-names></name><name><surname>Schwarz</surname><given-names>A.</given-names></name><name><surname>Gazzeri</surname><given-names>R.</given-names></name><name><surname>Reinert</surname><given-names>M.</given-names></name><name><surname>Widmer</surname><given-names>H.R.</given-names></name></person-group>
<article-title>Psychosocial and neurocognitive performance after spontaneous nonaneurysmal subarachnoid hemorrhage related to the apoe-epsilon4 genotype: A prospective 5-year follow-up study</article-title>
<source>J. Neurosurg.</source>
<year>2008</year>
<volume>109</volume>
<fpage>1019</fpage>
<lpage>1026</lpage>
<pub-id pub-id-type="doi">10.3171/JNS.2008.109.12.1019</pub-id>
<pub-id pub-id-type="pmid">19035714</pub-id></element-citation></ref><ref id="B75-ijms-17-00497"><label>75.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Adamski</surname><given-names>M.G.</given-names></name><name><surname>Golenia</surname><given-names>A.</given-names></name><name><surname>Turaj</surname><given-names>W.</given-names></name><name><surname>Baird</surname><given-names>A.E.</given-names></name><name><surname>Moskala</surname><given-names>M.</given-names></name><name><surname>Dziedzic</surname><given-names>T.</given-names></name><name><surname>Szczudlik</surname><given-names>A.</given-names></name><name><surname>Slowik</surname><given-names>A.</given-names></name><name><surname>Pera</surname><given-names>J.</given-names></name></person-group>
<article-title>The <italic>AGTR1</italic> gene <italic>A1166C</italic> polymorphism as a risk factor and outcome predictor of primary intracerebral and aneurysmal subarachnoid hemorrhages</article-title>
<source>Neurol. Neurochir. Pol.</source>
<year>2014</year>
<volume>48</volume>
<fpage>242</fpage>
<lpage>247</lpage>
<pub-id pub-id-type="doi">10.1016/j.pjnns.2014.07.007</pub-id>
<pub-id pub-id-type="pmid">25168322</pub-id></element-citation></ref><ref id="B76-ijms-17-00497"><label>76.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sun</surname><given-names>Q.</given-names></name><name><surname>Wu</surname><given-names>W.</given-names></name><name><surname>Hu</surname><given-names>Y.C.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>D.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>W.D.</given-names></name><name><surname>Ma</surname><given-names>B.</given-names></name><name><surname>Zhu</surname><given-names>J.H.</given-names></name><etal/></person-group>
<article-title>Early release of high-mobility group box 1 (hmgb1) from neurons in experimental subarachnoid hemorrhage <italic>in vivo</italic> and <italic>in vitro</italic></article-title>
<source>J. Neuroinflamm.</source>
<year>2014</year>
<volume>11</volume>
<fpage>106</fpage>
<pub-id pub-id-type="doi">10.1186/1742-2094-11-106</pub-id>
<pub-id pub-id-type="pmid">24924349</pub-id></element-citation></ref><ref id="B77-ijms-17-00497"><label>77.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Starke</surname><given-names>R.M.</given-names></name><name><surname>Chalouhi</surname><given-names>N.</given-names></name><name><surname>Jabbour</surname><given-names>P.M.</given-names></name><name><surname>Tjoumakaris</surname><given-names>S.I.</given-names></name><name><surname>Gonzalez</surname><given-names>L.F.</given-names></name><name><surname>Rosenwasser</surname><given-names>R.H.</given-names></name><name><surname>Wada</surname><given-names>K.</given-names></name><name><surname>Shimada</surname><given-names>K.</given-names></name><name><surname>Hasan</surname><given-names>D.M.</given-names></name><name><surname>Greig</surname><given-names>N.H.</given-names></name><etal/></person-group>
<article-title>Critical role of TNF-&#x003b1; in cerebral aneurysm formation and progression to rupture</article-title>
<source>J. Neuroinflamm.</source>
<year>2014</year>
<volume>11</volume>
<fpage>77</fpage>
<pub-id pub-id-type="doi">10.1186/1742-2094-11-77</pub-id>
<pub-id pub-id-type="pmid">24739142</pub-id></element-citation></ref><ref id="B78-ijms-17-00497"><label>78.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>S.</given-names></name><name><surname>Ma</surname><given-names>Q.</given-names></name><name><surname>Krafft</surname><given-names>P.R.</given-names></name><name><surname>Hu</surname><given-names>Q.</given-names></name><name><surname>Rolland</surname><given-names>W.</given-names><suffix>2nd</suffix></name><name><surname>Sherchan</surname><given-names>P.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Tang</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>J.H.</given-names></name></person-group>
<article-title>P2x7r/cryopyrin inflammasome axis inhibition reduces neuroinflammation after SAH</article-title>
<source>Neurobiol. Dis.</source>
<year>2013</year>
<volume>58</volume>
<fpage>296</fpage>
<lpage>307</lpage>
<pub-id pub-id-type="doi">10.1016/j.nbd.2013.06.011</pub-id>
<pub-id pub-id-type="pmid">23816751</pub-id></element-citation></ref><ref id="B79-ijms-17-00497"><label>79.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tosun</surname><given-names>C.</given-names></name><name><surname>Kurland</surname><given-names>D.B.</given-names></name><name><surname>Mehta</surname><given-names>R.</given-names></name><name><surname>Castellani</surname><given-names>R.J.</given-names></name><name><surname>deJong</surname><given-names>J.L.</given-names></name><name><surname>Kwon</surname><given-names>M.S.</given-names></name><name><surname>Woo</surname><given-names>S.K.</given-names></name><name><surname>Gerzanich</surname><given-names>V.</given-names></name><name><surname>Simard</surname><given-names>J.M.</given-names></name></person-group>
<article-title>Inhibition of the SUR1-TRPM4 channel reduces neuroinflammation and cognitive impairment in subarachnoid hemorrhage</article-title>
<source>Stroke</source>
<year>2013</year>
<volume>44</volume>
<fpage>3522</fpage>
<lpage>3528</lpage>
<pub-id pub-id-type="doi">10.1161/STROKEAHA.113.002904</pub-id>
<pub-id pub-id-type="pmid">24114458</pub-id></element-citation></ref><ref id="B80-ijms-17-00497"><label>80.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sacco</surname><given-names>S.</given-names></name><name><surname>Ornello</surname><given-names>R.</given-names></name><name><surname>Ripa</surname><given-names>P.</given-names></name><name><surname>Pistoia</surname><given-names>F.</given-names></name><name><surname>Carolei</surname><given-names>A.</given-names></name></person-group>
<article-title>Migraine and hemorrhagic stroke: A meta-analysis</article-title>
<source>Stroke</source>
<year>2013</year>
<volume>44</volume>
<fpage>3032</fpage>
<lpage>3038</lpage>
<pub-id pub-id-type="doi">10.1161/STROKEAHA.113.002465</pub-id>
<pub-id pub-id-type="pmid">24085027</pub-id></element-citation></ref><ref id="B81-ijms-17-00497"><label>81.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dumont</surname><given-names>T.</given-names></name><name><surname>Rughani</surname><given-names>A.</given-names></name><name><surname>Silver</surname><given-names>J.</given-names></name><name><surname>Tranmer</surname><given-names>B.I.</given-names></name></person-group>
<article-title>Diabetes mellitus increases risk of vasospasm following aneurysmal subarachnoid hemorrhage independent of glycemic control</article-title>
<source>Neurocrit. Care</source>
<year>2009</year>
<volume>11</volume>
<fpage>183</fpage>
<lpage>189</lpage>
<pub-id pub-id-type="doi">10.1007/s12028-009-9232-x</pub-id>
<pub-id pub-id-type="pmid">19472085</pub-id></element-citation></ref><ref id="B82-ijms-17-00497"><label>82.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rosen</surname><given-names>D.S.</given-names></name><name><surname>Amidei</surname><given-names>C.</given-names></name><name><surname>Tolentino</surname><given-names>J.</given-names></name><name><surname>Reilly</surname><given-names>C.</given-names></name><name><surname>Macdonald</surname><given-names>R.L.</given-names></name></person-group>
<article-title>Subarachnoid clot volume correlates with age, neurological grade, and blood pressure</article-title>
<source>Neurosurgery</source>
<year>2007</year>
<volume>60</volume>
<fpage>259</fpage>
<lpage>266</lpage>
<comment>discussion 257&#x02013;266</comment>
<pub-id pub-id-type="doi">10.1227/01.NEU.0000249271.56816.03</pub-id>
<pub-id pub-id-type="pmid">17290176</pub-id></element-citation></ref><ref id="B83-ijms-17-00497"><label>83.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mashaly</surname><given-names>H.A.</given-names></name><name><surname>Provencio</surname><given-names>J.J.</given-names></name></person-group>
<article-title>Inflammation as a link between brain injury and heart damage: The model of subarachnoid hemorrhage</article-title>
<source>Cleve. Clin. J. Med.</source>
<year>2008</year>
<volume>75</volume>
<issue>Suppl. 2</issue>
<fpage>S26</fpage>
<lpage>S30</lpage>
<pub-id pub-id-type="doi">10.3949/ccjm.75.Suppl_2.S26</pub-id>
<pub-id pub-id-type="pmid">18540142</pub-id></element-citation></ref><ref id="B84-ijms-17-00497"><label>84.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Acikgoz</surname><given-names>S.</given-names></name><name><surname>Edebali</surname><given-names>N.</given-names></name><name><surname>Barut</surname><given-names>F.</given-names></name><name><surname>Can</surname><given-names>M.</given-names></name><name><surname>Tekin</surname><given-names>I.O.</given-names></name><name><surname>Buyukuysal</surname><given-names>C.</given-names></name><name><surname>Acikgoz</surname><given-names>B.</given-names></name></person-group>
<article-title>Ischemia modified albumin increase indicating cardiac damage after experimental subarachnoid hemorrhage</article-title>
<source>BMC Neurosci.</source>
<year>2014</year>
<volume>15</volume>
<fpage>33</fpage>
<pub-id pub-id-type="doi">10.1186/1471-2202-15-33</pub-id>
<pub-id pub-id-type="pmid">24564759</pub-id></element-citation></ref><ref id="B85-ijms-17-00497"><label>85.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Friedrich</surname><given-names>V.</given-names></name><name><surname>Flores</surname><given-names>R.</given-names></name><name><surname>Muller</surname><given-names>A.</given-names></name><name><surname>Bi</surname><given-names>W.</given-names></name><name><surname>Peerschke</surname><given-names>E.I.</given-names></name><name><surname>Sehba</surname><given-names>F.A.</given-names></name></person-group>
<article-title>Reduction of neutrophil activity decreases early microvascular injury after subarachnoid haemorrhage</article-title>
<source>J. Neuroinflamm.</source>
<year>2011</year>
<volume>8</volume>
<fpage>103</fpage>
<pub-id pub-id-type="doi">10.1186/1742-2094-8-103</pub-id>
<pub-id pub-id-type="pmid">21854561</pub-id></element-citation></ref><ref id="B86-ijms-17-00497"><label>86.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schneider</surname><given-names>U.C.</given-names></name><name><surname>Schiffler</surname><given-names>J.</given-names></name><name><surname>Hakiy</surname><given-names>N.</given-names></name><name><surname>Horn</surname><given-names>P.</given-names></name><name><surname>Vajkoczy</surname><given-names>P.</given-names></name></person-group>
<article-title>Functional analysis of pro-inflammatory properties within the cerebrospinal fluid after subarachnoid hemorrhage <italic>in vivo</italic> and <italic>in vitro</italic></article-title>
<source>J. Neuroinflamm.</source>
<year>2012</year>
<volume>9</volume>
<fpage>28</fpage>
<pub-id pub-id-type="doi">10.1186/1742-2094-9-28</pub-id>
<pub-id pub-id-type="pmid">22316109</pub-id></element-citation></ref><ref id="B87-ijms-17-00497"><label>87.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stranahan</surname><given-names>A.M.</given-names></name></person-group>
<article-title>Models and mechanisms for hippocampal dysfunction in obesity and diabetes</article-title>
<source>Neuroscience</source>
<year>2015</year>
<volume>309</volume>
<fpage>125</fpage>
<lpage>139</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroscience.2015.04.045</pub-id>
<pub-id pub-id-type="pmid">25934036</pub-id></element-citation></ref><ref id="B88-ijms-17-00497"><label>88.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Aguilar-Valles</surname><given-names>A.</given-names></name><name><surname>Inoue</surname><given-names>W.</given-names></name><name><surname>Rummel</surname><given-names>C.</given-names></name><name><surname>Luheshi</surname><given-names>G.N.</given-names></name></person-group>
<article-title>Obesity, adipokines and neuroinflammation</article-title>
<source>Neuropharmacology</source>
<year>2015</year>
<volume>96</volume>
<fpage>124</fpage>
<lpage>134</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2014.12.023</pub-id>
<pub-id pub-id-type="pmid">25582291</pub-id></element-citation></ref><ref id="B89-ijms-17-00497"><label>89.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Drake</surname><given-names>C.</given-names></name><name><surname>Boutin</surname><given-names>H.</given-names></name><name><surname>Jones</surname><given-names>M.S.</given-names></name><name><surname>Denes</surname><given-names>A.</given-names></name><name><surname>McColl</surname><given-names>B.W.</given-names></name><name><surname>Selvarajah</surname><given-names>J.R.</given-names></name><name><surname>Hulme</surname><given-names>S.</given-names></name><name><surname>Georgiou</surname><given-names>R.F.</given-names></name><name><surname>Hinz</surname><given-names>R.</given-names></name><name><surname>Gerhard</surname><given-names>A.</given-names></name><etal/></person-group>
<article-title>Brain inflammation is induced by co-morbidities and risk factors for stroke</article-title>
<source>Brain Behav. Immun.</source>
<year>2011</year>
<volume>25</volume>
<fpage>1113</fpage>
<lpage>1122</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbi.2011.02.008</pub-id>
<pub-id pub-id-type="pmid">21356305</pub-id></element-citation></ref><ref id="B90-ijms-17-00497"><label>90.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Koso</surname><given-names>M.</given-names></name><name><surname>Dizdarevic</surname><given-names>K.</given-names></name><name><surname>Sose-Selimotic</surname><given-names>J.</given-names></name></person-group>
<article-title>Everyday memory in microsurgically treated patients after subarachnoid hemorrhage</article-title>
<source>J. Clin. Med. Res.</source>
<year>2015</year>
<volume>7</volume>
<fpage>225</fpage>
<lpage>231</lpage>
<pub-id pub-id-type="doi">10.14740/jocmr2073w</pub-id>
<pub-id pub-id-type="pmid">25699118</pub-id></element-citation></ref><ref id="B91-ijms-17-00497"><label>91.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tada</surname><given-names>Y.</given-names></name><name><surname>Wada</surname><given-names>K.</given-names></name><name><surname>Shimada</surname><given-names>K.</given-names></name><name><surname>Makino</surname><given-names>H.</given-names></name><name><surname>Liang</surname><given-names>E.I.</given-names></name><name><surname>Murakami</surname><given-names>S.</given-names></name><name><surname>Kudo</surname><given-names>M.</given-names></name><name><surname>Kitazato</surname><given-names>K.T.</given-names></name><name><surname>Nagahiro</surname><given-names>S.</given-names></name><name><surname>Hashimoto</surname><given-names>T.</given-names></name></person-group>
<article-title>Roles of hypertension in the rupture of intracranial aneurysms</article-title>
<source>Stroke</source>
<year>2014</year>
<volume>45</volume>
<fpage>579</fpage>
<lpage>586</lpage>
<pub-id pub-id-type="doi">10.1161/STROKEAHA.113.003072</pub-id>
<pub-id pub-id-type="pmid">24370755</pub-id></element-citation></ref><ref id="B92-ijms-17-00497"><label>92.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bashir</surname><given-names>A.</given-names></name><name><surname>Andresen</surname><given-names>M.</given-names></name><name><surname>Bartek</surname><given-names>J.</given-names><suffix>Jr.</suffix></name><name><surname>Cortsen</surname><given-names>M.</given-names></name><name><surname>Eskesen</surname><given-names>V.</given-names></name><name><surname>Wagner</surname><given-names>A.</given-names></name></person-group>
<article-title>Intra-arterial nimodipine for cerebral vasospasm after subarachnoid haemorrhage: Influence on clinical course and predictors of clinical outcome</article-title>
<source>Neuroradiol. J.</source>
<year>2016</year>
<pub-id pub-id-type="doi">10.1177/1971400915626429</pub-id>
<pub-id pub-id-type="pmid">26825134</pub-id></element-citation></ref><ref id="B93-ijms-17-00497"><label>93.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Singh</surname><given-names>N.</given-names></name><name><surname>Hopkins</surname><given-names>S.J.</given-names></name><name><surname>Hulme</surname><given-names>S.</given-names></name><name><surname>Galea</surname><given-names>J.P.</given-names></name><name><surname>Hoadley</surname><given-names>M.</given-names></name><name><surname>Vail</surname><given-names>A.</given-names></name><name><surname>Hutchinson</surname><given-names>P.J.</given-names></name><name><surname>Grainger</surname><given-names>S.</given-names></name><name><surname>Rothwell</surname><given-names>N.J.</given-names></name><name><surname>King</surname><given-names>A.T.</given-names></name><etal/></person-group>
<article-title>The effect of intravenous interleukin-1 receptor antagonist on inflammatory mediators in cerebrospinal fluid after subarachnoid haemorrhage: A phase ii randomised controlled trial</article-title>
<source>J. Neuroinflamm.</source>
<year>2014</year>
<volume>11</volume>
<fpage>1</fpage>
<pub-id pub-id-type="doi">10.1186/1742-2094-11-1</pub-id>
<pub-id pub-id-type="pmid">24383930</pub-id></element-citation></ref><ref id="B94-ijms-17-00497"><label>94.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>G.</given-names></name><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Feng</surname><given-names>D.</given-names></name><name><surname>Hu</surname><given-names>T.</given-names></name><name><surname>Fang</surname><given-names>Q.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name></person-group>
<article-title>Expression of NR2B in different brain regions and effect of NR2B antagonism on learning deficits after experimental subarachnoid hemorrhage</article-title>
<source>Neuroscience</source>
<year>2013</year>
<volume>231</volume>
<fpage>136</fpage>
<lpage>144</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroscience.2012.11.024</pub-id>
<pub-id pub-id-type="pmid">23219940</pub-id></element-citation></ref><ref id="B95-ijms-17-00497"><label>95.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Boyko</surname><given-names>M.</given-names></name><name><surname>Azab</surname><given-names>A.N.</given-names></name><name><surname>Kuts</surname><given-names>R.</given-names></name><name><surname>Gruenbaum</surname><given-names>B.F.</given-names></name><name><surname>Gruenbaum</surname><given-names>S.E.</given-names></name><name><surname>Melamed</surname><given-names>I.</given-names></name><name><surname>Brotfain</surname><given-names>E.</given-names></name><name><surname>Shapira</surname><given-names>Y.</given-names></name><name><surname>Cesnulis</surname><given-names>E.</given-names></name><name><surname>Zlotnik</surname><given-names>A.</given-names></name></person-group>
<article-title>The neuro-behavioral profile in rats after subarachnoid hemorrhage</article-title>
<source>Brain Res.</source>
<year>2013</year>
<volume>1491</volume>
<fpage>109</fpage>
<lpage>116</lpage>
<pub-id pub-id-type="doi">10.1016/j.brainres.2012.10.061</pub-id>
<pub-id pub-id-type="pmid">23123210</pub-id></element-citation></ref><ref id="B96-ijms-17-00497"><label>96.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Povlsen</surname><given-names>G.K.</given-names></name><name><surname>Johansson</surname><given-names>S.E.</given-names></name><name><surname>Larsen</surname><given-names>C.C.</given-names></name><name><surname>Samraj</surname><given-names>A.K.</given-names></name><name><surname>Edvinsson</surname><given-names>L.</given-names></name></person-group>
<article-title>Early events triggering delayed vasoconstrictor receptor upregulation and cerebral ischemia after subarachnoid hemorrhage</article-title>
<source>BMC Neurosci.</source>
<year>2013</year>
<volume>14</volume>
<fpage>34</fpage>
<pub-id pub-id-type="doi">10.1186/1471-2202-14-34</pub-id>
<pub-id pub-id-type="pmid">23496889</pub-id></element-citation></ref><ref id="B97-ijms-17-00497"><label>97.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Povlsen</surname><given-names>G.K.</given-names></name><name><surname>Edvinsson</surname><given-names>L.</given-names></name></person-group>
<article-title>Mek1/2 inhibitor u0126 but not endothelin receptor antagonist clazosentan reduces upregulation of cerebrovascular contractile receptors and delayed cerebral ischemia, and improves outcome after subarachnoid hemorrhage in rats</article-title>
<source>J. Cereb. Blood Flow Metab.</source>
<year>2015</year>
<volume>35</volume>
<fpage>329</fpage>
<lpage>337</lpage>
<pub-id pub-id-type="doi">10.1038/jcbfm.2014.205</pub-id>
<pub-id pub-id-type="pmid">25407271</pub-id></element-citation></ref><ref id="B98-ijms-17-00497"><label>98.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maddahi</surname><given-names>A.</given-names></name><name><surname>Povlsen</surname><given-names>G.K.</given-names></name><name><surname>Edvinsson</surname><given-names>L.</given-names></name></person-group>
<article-title>Regulation of enhanced cerebrovascular expression of proinflammatory mediators in experimental subarachnoid hemorrhage via the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathway</article-title>
<source>J. Neuroinflamm.</source>
<year>2012</year>
<volume>9</volume>
<fpage>274</fpage>
<pub-id pub-id-type="doi">10.1186/1742-2094-9-274</pub-id>
<pub-id pub-id-type="pmid">23259581</pub-id></element-citation></ref><ref id="B99-ijms-17-00497"><label>99.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tian</surname><given-names>D.S.</given-names></name><name><surname>Liu</surname><given-names>J.L.</given-names></name><name><surname>Xie</surname><given-names>M.J.</given-names></name><name><surname>Zhan</surname><given-names>Y.</given-names></name><name><surname>Qu</surname><given-names>W.S.</given-names></name><name><surname>Yu</surname><given-names>Z.Y.</given-names></name><name><surname>Tang</surname><given-names>Z.P.</given-names></name><name><surname>Pan</surname><given-names>D.J.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name></person-group>
<article-title>Tamoxifen attenuates inflammatory-mediated damage and improves functional outcome after spinal cord injury in rats</article-title>
<source>J. Neurochem.</source>
<year>2009</year>
<volume>109</volume>
<fpage>1658</fpage>
<lpage>1667</lpage>
<pub-id pub-id-type="doi">10.1111/j.1471-4159.2009.06077.x</pub-id>
<pub-id pub-id-type="pmid">19457130</pub-id></element-citation></ref><ref id="B100-ijms-17-00497"><label>100.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xie</surname><given-names>Q.</given-names></name><name><surname>Guan</surname><given-names>J.</given-names></name><name><surname>Wu</surname><given-names>G.</given-names></name><name><surname>Xi</surname><given-names>G.</given-names></name><name><surname>Keep</surname><given-names>R.F.</given-names></name><name><surname>Hua</surname><given-names>Y.</given-names></name></person-group>
<article-title>Tamoxifen treatment for intracerebral hemorrhage</article-title>
<source>Acta Neurochir. Suppl.</source>
<year>2011</year>
<volume>111</volume>
<fpage>271</fpage>
<lpage>275</lpage>
<pub-id pub-id-type="pmid">21725767</pub-id></element-citation></ref><ref id="B101-ijms-17-00497"><label>101.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Osuka</surname><given-names>K.</given-names></name><name><surname>Feustel</surname><given-names>P.J.</given-names></name><name><surname>Mongin</surname><given-names>A.A.</given-names></name><name><surname>Tranmer</surname><given-names>B.I.</given-names></name><name><surname>Kimelberg</surname><given-names>H.K.</given-names></name></person-group>
<article-title>Tamoxifen inhibits nitrotyrosine formation after reversible middle cerebral artery occlusion in the rat</article-title>
<source>J. Neurochem.</source>
<year>2001</year>
<volume>76</volume>
<fpage>1842</fpage>
<lpage>1850</lpage>
<pub-id pub-id-type="doi">10.1046/j.1471-4159.2001.00198.x</pub-id>
<pub-id pub-id-type="pmid">11259502</pub-id></element-citation></ref><ref id="B102-ijms-17-00497"><label>102.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Feng</surname><given-names>Y.</given-names></name><name><surname>Fratkins</surname><given-names>J.D.</given-names></name><name><surname>LeBlanc</surname><given-names>M.H.</given-names></name></person-group>
<article-title>Treatment with tamoxifen reduces hypoxic-ischemic brain injury in neonatal rats</article-title>
<source>Eur. J. Pharmacol.</source>
<year>2004</year>
<volume>484</volume>
<fpage>65</fpage>
<lpage>74</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejphar.2003.10.048</pub-id>
<pub-id pub-id-type="pmid">14729383</pub-id></element-citation></ref><ref id="B103-ijms-17-00497"><label>103.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xu</surname><given-names>H.</given-names></name><name><surname>Testai</surname><given-names>F.D.</given-names></name><name><surname>Valyi-Nagy</surname><given-names>T.</given-names></name><name><surname>N Pavuluri</surname><given-names>M.</given-names></name><name><surname>Zhai</surname><given-names>F.</given-names></name><name><surname>Nanegrungsunk</surname><given-names>D.</given-names></name><name><surname>Paisansathan</surname><given-names>C.</given-names></name><name><surname>Pelligrino</surname><given-names>D.A.</given-names></name></person-group>
<article-title>Vap-1 blockade prevents subarachnoid hemorrhage-associated cerebrovascular dilating dysfunction via repression of a neutrophil recruitment-related mechanism</article-title>
<source>Brain Res.</source>
<year>2015</year>
<volume>1603</volume>
<fpage>141</fpage>
<lpage>149</lpage>
<pub-id pub-id-type="doi">10.1016/j.brainres.2015.01.047</pub-id>
<pub-id pub-id-type="pmid">25662771</pub-id></element-citation></ref><ref id="B104-ijms-17-00497"><label>104.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xu</surname><given-names>H.L.</given-names></name><name><surname>Pelligrino</surname><given-names>D.A.</given-names></name><name><surname>Paisansathan</surname><given-names>C.</given-names></name><name><surname>Testai</surname><given-names>F.D.</given-names></name></person-group>
<article-title>Protective role of fingolimod (FTY720) in rats subjected to subarachnoid hemorrhage</article-title>
<source>J. Neuroinflamm.</source>
<year>2015</year>
<volume>12</volume>
<fpage>16</fpage>
<pub-id pub-id-type="doi">10.1186/s12974-015-0234-7</pub-id>
<pub-id pub-id-type="pmid">25622980</pub-id></element-citation></ref><ref id="B105-ijms-17-00497"><label>105.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lin</surname><given-names>C.L.</given-names></name><name><surname>Dumont</surname><given-names>A.S.</given-names></name><name><surname>Calisaneller</surname><given-names>T.</given-names></name><name><surname>Kwan</surname><given-names>A.L.</given-names></name><name><surname>Hwong</surname><given-names>S.L.</given-names></name><name><surname>Lee</surname><given-names>K.S.</given-names></name></person-group>
<article-title>Monoclonal antibody against e selectin attenuates subarachnoid hemorrhage-induced cerebral vasospasm</article-title>
<source>Surg. Neuro.</source>
<year>2005</year>
<volume>64</volume>
<fpage>201</fpage>
<lpage>205</lpage>
<comment>discussion 205&#x02013;206</comment>
<pub-id pub-id-type="doi">10.1016/j.surneu.2005.04.038</pub-id>
<pub-id pub-id-type="pmid">16099244</pub-id></element-citation></ref><ref id="B106-ijms-17-00497"><label>106.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pradilla</surname><given-names>G.</given-names></name><name><surname>Wang</surname><given-names>P.P.</given-names></name><name><surname>Legnani</surname><given-names>F.G.</given-names></name><name><surname>Ogata</surname><given-names>L.</given-names></name><name><surname>Dietsch</surname><given-names>G.N.</given-names></name><name><surname>Tamargo</surname><given-names>R.J.</given-names></name></person-group>
<article-title>Prevention of vasospasm by anti-CD11/CD18 monoclonal antibody therapy following subarachnoid hemorrhage in rabbits</article-title>
<source>J. Neurosurg.</source>
<year>2004</year>
<volume>101</volume>
<fpage>88</fpage>
<lpage>92</lpage>
<pub-id pub-id-type="doi">10.3171/jns.2004.101.1.0088</pub-id>
<pub-id pub-id-type="pmid">15255256</pub-id></element-citation></ref><ref id="B107-ijms-17-00497"><label>107.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Provencio</surname><given-names>J.J.</given-names></name><name><surname>Altay</surname><given-names>T.</given-names></name><name><surname>Smithason</surname><given-names>S.</given-names></name><name><surname>Moore</surname><given-names>S.K.</given-names></name><name><surname>Ransohoff</surname><given-names>R.M.</given-names></name></person-group>
<article-title>Depletion of Ly6g/C (+) cells ameliorates delayed cerebral vasospasm in subarachnoid hemorrhage</article-title>
<source>J. Neuroimmunol.</source>
<year>2011</year>
<volume>232</volume>
<fpage>94</fpage>
<lpage>100</lpage>
<pub-id pub-id-type="doi">10.1016/j.jneuroim.2010.10.016</pub-id>
<pub-id pub-id-type="pmid">21059474</pub-id></element-citation></ref><ref id="B108-ijms-17-00497"><label>108.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Daley</surname><given-names>J.M.</given-names></name><name><surname>Thomay</surname><given-names>A.A.</given-names></name><name><surname>Connolly</surname><given-names>M.D.</given-names></name><name><surname>Reichner</surname><given-names>J.S.</given-names></name><name><surname>Albina</surname><given-names>J.E.</given-names></name></person-group>
<article-title>Use of ly6g-specific monoclonal antibody to deplete neutrophils in mice</article-title>
<source>J. Leukoc. Biol.</source>
<year>2008</year>
<volume>83</volume>
<fpage>64</fpage>
<lpage>70</lpage>
<pub-id pub-id-type="doi">10.1189/jlb.0407247</pub-id>
<pub-id pub-id-type="pmid">17884993</pub-id></element-citation></ref><ref id="B109-ijms-17-00497"><label>109.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Simard</surname><given-names>J.M.</given-names></name><name><surname>Tosun</surname><given-names>C.</given-names></name><name><surname>Ivanova</surname><given-names>S.</given-names></name><name><surname>Kurland</surname><given-names>D.B.</given-names></name><name><surname>Hong</surname><given-names>C.</given-names></name><name><surname>Radecki</surname><given-names>L.</given-names></name><name><surname>Gisriel</surname><given-names>C.</given-names></name><name><surname>Mehta</surname><given-names>R.</given-names></name><name><surname>Schreibman</surname><given-names>D.</given-names></name><name><surname>Gerzanich</surname><given-names>V.</given-names></name></person-group>
<article-title>Heparin reduces neuroinflammation and transsynaptic neuronal apoptosis in a model of subarachnoid hemorrhage</article-title>
<source>Transl. Stroke Res.</source>
<year>2012</year>
<volume>3</volume>
<fpage>155</fpage>
<lpage>165</lpage>
<pub-id pub-id-type="doi">10.1007/s12975-012-0166-9</pub-id>
<pub-id pub-id-type="pmid">22707992</pub-id></element-citation></ref><ref id="B110-ijms-17-00497"><label>110.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kurland</surname><given-names>D.B.</given-names></name><name><surname>Tosun</surname><given-names>C.</given-names></name><name><surname>Pampori</surname><given-names>A.</given-names></name><name><surname>Karimy</surname><given-names>J.K.</given-names></name><name><surname>Caffes</surname><given-names>N.M.</given-names></name><name><surname>Gerzanich</surname><given-names>V.</given-names></name><name><surname>Simard</surname><given-names>J.M.</given-names></name></person-group>
<article-title>Glibenclamide for the treatment of acute CNS injury</article-title>
<source>Pharmaceuticals</source>
<year>2013</year>
<volume>6</volume>
<fpage>1287</fpage>
<lpage>1303</lpage>
<pub-id pub-id-type="doi">10.3390/ph6101287</pub-id>
<pub-id pub-id-type="pmid">24275850</pub-id></element-citation></ref><ref id="B111-ijms-17-00497"><label>111.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dumont</surname><given-names>A.S.</given-names></name><name><surname>Dumont</surname><given-names>R.J.</given-names></name><name><surname>Chow</surname><given-names>M.M.</given-names></name><name><surname>Lin</surname><given-names>C.L.</given-names></name><name><surname>Calisaneller</surname><given-names>T.</given-names></name><name><surname>Ley</surname><given-names>K.F.</given-names></name><name><surname>Kassell</surname><given-names>N.F.</given-names></name><name><surname>Lee</surname><given-names>K.S.</given-names></name></person-group>
<article-title>Cerebral vasospasm after subarachnoid hemorrhage: Putative role of inflammation</article-title>
<source>Neurosurgery</source>
<year>2003</year>
<volume>53</volume>
<fpage>123</fpage>
<lpage>133</lpage>
<pub-id pub-id-type="doi">10.1227/01.NEU.0000068863.37133.9E</pub-id>
<pub-id pub-id-type="pmid">12823881</pub-id></element-citation></ref><ref id="B112-ijms-17-00497"><label>112.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Polin</surname><given-names>R.S.</given-names></name><name><surname>Bavbek</surname><given-names>M.</given-names></name><name><surname>Shaffrey</surname><given-names>M.E.</given-names></name><name><surname>Billups</surname><given-names>K.</given-names></name><name><surname>Bogaev</surname><given-names>C.A.</given-names></name><name><surname>Kassell</surname><given-names>N.F.</given-names></name><name><surname>Lee</surname><given-names>K.S.</given-names></name></person-group>
<article-title>Detection of soluble e-selectin, icam-1, vcam-1, and l-selectin in the cerebrospinal fluid of patients after subarachnoid hemorrhage</article-title>
<source>J. Neurosurg.</source>
<year>1998</year>
<volume>89</volume>
<fpage>559</fpage>
<lpage>567</lpage>
<pub-id pub-id-type="doi">10.3171/jns.1998.89.4.0559</pub-id>
<pub-id pub-id-type="pmid">9761049</pub-id></element-citation></ref><ref id="B113-ijms-17-00497"><label>113.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Tang</surname><given-names>K.</given-names></name><name><surname>Huang</surname><given-names>R.Q.</given-names></name><name><surname>Zhuang</surname><given-names>Z.</given-names></name><name><surname>Cheng</surname><given-names>H.L.</given-names></name><name><surname>Yin</surname><given-names>H.X.</given-names></name><name><surname>Shi</surname><given-names>J.X.</given-names></name></person-group>
<article-title>Therapeutic potential of peroxisome proliferator-activated receptor gamma agonist rosiglitazone in cerebral vasospasm after a rat experimental subarachnoid hemorrhage model</article-title>
<source>J. Neurol. Sci.</source>
<year>2011</year>
<volume>305</volume>
<fpage>85</fpage>
<lpage>91</lpage>
<pub-id pub-id-type="doi">10.1016/j.jns.2011.03.006</pub-id>
<pub-id pub-id-type="pmid">21440907</pub-id></element-citation></ref><ref id="B114-ijms-17-00497"><label>114.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>X.D.</given-names></name><name><surname>Zhuang</surname><given-names>Z.</given-names></name><name><surname>Xue</surname><given-names>Y.J.</given-names></name><name><surname>Cheng</surname><given-names>H.L.</given-names></name><name><surname>Yin</surname><given-names>H.X.</given-names></name><name><surname>Shi</surname><given-names>J.X.</given-names></name></person-group>
<article-title>Peroxisome proliferator-activated receptor gamma agonist rosiglitazone attenuates oxyhemoglobin-induced toll-like receptor 4 expression in vascular smooth muscle cells</article-title>
<source>Brain Res.</source>
<year>2010</year>
<volume>1322</volume>
<fpage>102</fpage>
<lpage>108</lpage>
<pub-id pub-id-type="doi">10.1016/j.brainres.2010.01.073</pub-id>
<pub-id pub-id-type="pmid">20132800</pub-id></element-citation></ref><ref id="B115-ijms-17-00497"><label>115.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Germano</surname><given-names>A.</given-names></name><name><surname>Caffo</surname><given-names>M.</given-names></name><name><surname>Angileri</surname><given-names>F.F.</given-names></name><name><surname>Arcadi</surname><given-names>F.</given-names></name><name><surname>Newcomb-Fernandez</surname><given-names>J.</given-names></name><name><surname>Caruso</surname><given-names>G.</given-names></name><name><surname>Meli</surname><given-names>F.</given-names></name><name><surname>Pineda</surname><given-names>J.A.</given-names></name><name><surname>Lewis</surname><given-names>S.B.</given-names></name><name><surname>Wang</surname><given-names>K.K.</given-names></name><etal/></person-group>
<article-title>NMDA receptor antagonist felbamate reduces behavioral deficits and blood-brain barrier permeability changes after experimental subarachnoid hemorrhage in the rat</article-title>
<source>J. Neurotrauma</source>
<year>2007</year>
<volume>24</volume>
<fpage>732</fpage>
<lpage>744</lpage>
<pub-id pub-id-type="doi">10.1089/neu.2006.0181</pub-id>
<pub-id pub-id-type="pmid">17439355</pub-id></element-citation></ref><ref id="B116-ijms-17-00497"><label>116.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Garzon-Muvdi</surname><given-names>T.</given-names></name><name><surname>Pradilla</surname><given-names>G.</given-names></name><name><surname>Ruzevick</surname><given-names>J.J.</given-names></name><name><surname>Bender</surname><given-names>M.</given-names></name><name><surname>Edwards</surname><given-names>L.</given-names></name><name><surname>Grossman</surname><given-names>R.</given-names></name><name><surname>Zhao</surname><given-names>M.</given-names></name><name><surname>Rudek</surname><given-names>M.A.</given-names></name><name><surname>Riggins</surname><given-names>G.</given-names></name><name><surname>Levy</surname><given-names>A.</given-names></name><etal/></person-group>
<article-title>A glutamate receptor antagonist, S-4-Carboxyphenylglycine (S-4-CPG), inhibits vasospasm after subarachnoid hemorrhage in haptoglobin 2-2 mice</article-title>
<source>Neurosurgery</source>
<year>2013</year>
<volume>73</volume>
<fpage>719</fpage>
<lpage>728</lpage>
<pub-id pub-id-type="doi">10.1227/NEU.0000000000000080</pub-id>
<pub-id pub-id-type="pmid">23842553</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="ijms-17-00497-f001" position="float"><label>Figure 1</label><caption><p>Red blood cell breakdown causes the release of heme, hemin, and methemoglobin. Through interactions with toll-like receptors on microglia, high mobility group box 1 protein is increased. This increase leads to downstream activation of NF&#x003ba;B and the release of proinflammatory cytokines.</p></caption><graphic xlink:href="ijms-17-00497-g001"/></fig><fig id="ijms-17-00497-f002" position="float"><label>Figure 2</label><caption><p>Following aneursym rupture, the brain stem can become ischemic and trigger heart damage. Damaged heart tissue can subsequently contribute to the inflammatory milieu following subarachnoid hemorrhage. Inflammation from heart abnormalities triggers the infiltration of peripheral immune cells into the brain as indicated by the arrows. This step-wise process further exacerbates neuroinflammation. Persistent neuroinflammation can lead to long-term cognitive and behavioral deficits.</p></caption><graphic xlink:href="ijms-17-00497-g002"/></fig><table-wrap id="ijms-17-00497-t001" position="float"><object-id pub-id-type="pii">ijms-17-00497-t001_Table 1</object-id><label>Table 1</label><caption><p>Preclinical and clinical models of Subarachnoid Hemorrhage treatment.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sex/Species/Age</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Model</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Target</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Outcome Measures</th></tr></thead><tbody><tr><td colspan="6" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">(a) Common cisternal SAH model</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Polvsen &#x00026; Edvinsson 2015</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Male <break/>SD Rats <break/>2&#x02013;3 months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cisternal blood infusion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">U0126</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MEK1/2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neurological score; Behavioral deficits; Cerebral blood flow; Endothelin receptor</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Maddahi <italic>et al.</italic>, 2012</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Male <break/>SD Rats <break/>2&#x02013;3 months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cisternal blood infusion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">U0126</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MEK1/2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neurological score; MAPK pathway; Pro-inflammatory activity; Matrix Metalloproteinase</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Zhang <italic>et al.</italic>, 2014</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Male <break/>SD Rats <break/>2&#x02013;3 months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cisternal blood infusion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Astaxanthin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">General Anti-oxidant Anti-inflammatory</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neurological score; Blood-brain barrier permeability; Edema; Pro-inflammatory activity; Leukocyte activity; Neuronal cell death</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pradilla <italic>et al.</italic>, 2004</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">New Zealand White Rabbit <break/>1.5&#x02013;2.5 kg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cisternal blood infusion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antibody</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD11/CD18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Blood vessel diameter (Vasospasm); Leukocyte activity</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Provencio <italic>et al.</italic>, 2011</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Male <break/>C57 Mice <break/>2&#x02013;3 months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cisternal blood infusion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antibody</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lymphocyte antigen 6 complex locus G6D (Myeloid cells)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Blood vessel diameter (Vasospasm); Leukocyte activity; Behavioral deficits; Microglial response</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lin <italic>et al.</italic>, 2005</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Male <break/>C57 Mice <break/>30&#x02013;35 g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cisternal blood infusion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antibody</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">E-Selectin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Blood vessel diameter (Vasospasm); Leukocyte activity</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Wu <italic>et al.</italic>, 2011</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Male <break/>SD Rats <break/>300&#x02013;350 g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cisternal blood infusion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rosiglitazone</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Peroxisome proliferator-activated receptor gamma agonist</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Blood vessel diameter (Vasospasm); Leukocyte activity; Pro-inflammatory activity</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Guresir <italic>et al.</italic>, 2013</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Male <break/>SD Rats <break/>250&#x02013;350 g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cisternal blood infusion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">human recombinant Erythropoietin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Erythropoietin receptor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neurological score; Blood vessel diameter (Vasospasm); Neuronal cell death</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Germano <italic>et al.</italic>, 2007</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Male <break/>SD Rats <break/>250 g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cisternal blood infusion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Felbamate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>N</italic>-methyl-<sc>d</sc>-aspartate receptor antagonist</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Blood-brain barrier permeability; Behavioral deficits; Body weight</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Garzon-Muvdi <italic>et al.</italic>, 2013</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C57 Mice <break/>22&#x02013;30 g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cisternal blood infusion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S-4-carboxy-phenylglycine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Glutamate receptor antagonist</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Blood vessel diameter (Vasospasm); Leukocyte activity;</td></tr><tr><td colspan="6" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">(b) Clinically-relevant SAH models</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Xu <italic>et al.</italic>, 2015</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Male <break/>SD Rats <break/>2&#x02013;3 months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Endovascular puncture</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LJP-1586</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Semicarbazide-sensitive amine oxidase inhibitor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neurological score; Leukocyte activity; Microvascular damage</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Xu <italic>et al.</italic>, 2015</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Male <break/>SD Rats <break/>2&#x02013;3 months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Endovascular puncture</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fingolimod</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sphingosine-1-phosphate receptor modulator</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neurological score; Leukocyte activity; Microvascular damage</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Simard <italic>et al.</italic>, 2012</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Male <break/>Wistar Rats <break/>300&#x02013;350 g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Entorhinal cortex blood infusion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Heparin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antithrombin III activator</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Demyelination; Neurodegeneration; Pro-inflammatory activity</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tosun <italic>et al.</italic>, 2013</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Male <break/>Wistar Rats <break/>300&#x02013;350 g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Entorhinal cortex blood infusion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Glibenclamide</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sur1-Trpm4 channel inhibitor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neurodegeneration; Behavioral deficits</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Makino <italic>et al.</italic>, 2012</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Male <break/>C57 Mice <break/>2&#x02013;3 months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Induced hypertension + Elastase injection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tetracycline Derivatives</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inflammatory Cytokines</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neurological score; Aneurysm rupture at 6 days</td></tr><tr><td colspan="6" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">(c) Clinical Trials for SAH</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Singh <italic>et al.</italic>, 2014</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical Trials</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anakinra</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Interleukin-1 receptor anatagonist</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Glasgow outcome score; Blood plasma and cerebral spinal fluid levels of Interleukin-6 between 6 and 24 h</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ma <italic>et al.</italic>, 2012</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical Trials</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clazosentan</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Endothelin receptor antagonist</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Glasgow coma score; Post-SAH vasospasm; Late cerebral ischemia</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Springborg <italic>et al.</italic>, 2007</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical Trials</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Erythropoietin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Erythropoietin receptor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Glasgow outcome score; Transcranial Doppler flow velocity; vasospasm; jugular venous oximetry; Brain injury markers; Blood-brain barrier integrity</td></tr></tbody></table></table-wrap></floats-group></article>